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  Resumen 
La fibrosis pulmonar idiopática (FPI) es una enfermedad degenerativa de los 
pulmones. Los pacientes presentan una supervivencia media tras el diagnóstico de 2 
a 3 años. La pérdida de células alveolares tipo 2 (ATII) y la pérdida de la capacidad 
regenerativa de los pulmones son características de la enfermedad. Mutaciones en los 
componentes de la enzima telomerasa o en proteínas relacionadas con la protección 
de los telómeros se han encontrado tanto en casos esporádicos como familiares. 
Telómeros críticamente cortos o disfuncionales pueden comprometer la regeneración 
tisular y son un factor de riesgo para el desarrollo de FPI. Nuevas estrategias y 
tratamientos son necesarios, sin embargo, la falta de modelos murinos que recapitulen 
la enfermedad humana han obstaculizado nuevos avances al respecto.  
Durante esta Tesis Doctoral hemos generado dos modelos murinos independientes de 
FPI producida por disfunción telomérica. En un modelo, se llevó a cabo la deleción de 
Trf1 en células ATII para producir una disfunción telomérica severa. En un segundo 
modelo, ratones con telómeros críticamente cortos, deficientes en telomerasa, fueron 
sometidos a un agente inductor de daño pulmonar, la bleomicina. En ambos modelos 
se desarrolló fibrosis pulmonar debido a daño telomérico. En ambos modelos también 
se observó la pérdida de función pulmonar debido al reemplazamiento de diferentes 
tipos celulares por tejido fibrótico e infiltrado inflamatorio. En conclusión, ambos 
modelos proporcionan una prueba del papel causal del daño en el ADN telomérico en 
el desarrollo de la FPI e identifican a los telómeros como nuevas dianas terapéuticas. 
El modelo de FPI inducido por telómeros cortos (ratones deficientes para Tert tratados 
con bleomicina) se utilizó posteriormente para comprobar la eficacia terapéutica de la 
re-expresión de telomerasa. Para ello usamos una estrategia de terapia génica con el 
vector AAV9 portando el gen Tert de la subunidad catalítica de la telomerasa. 
Encontramos que AAV9-Tert transduce preferentemente las células ATII. Se realizaró 
un seguimiento radiológico tras el tratamiento con AAV9-Tert y reveló una reversión de 
la fibrosis y remisión total en el 50% de los casos a las 7 semanas tras el diagnóstico, 
mientras que los animales tratados con el vector vacío seguían mostrando focos de 
fibrosis severa. Esta regresión fue asociada con un incremento de la longitud 
telomérica en células ATII, una disminución del daño en el ADN y disminución de la 
apoptosis y de la senescencia. El tratamiento con AAV9-Tert incrementó la 
proliferación de las células ATII y resultó en cambios en la expresión génica indicativos 
de la disminución de fibrosis e inducción de regeneración. Los resultados obtenidos en 
esta Tesis indican que la terapia génica con telomerasa constituye un tratamiento 
efectivo para la FPI asociada a telómeros cortos. 
  Abstract 
Idiopathic pulmonary fibrosis (IPF) is a degenerative disease of the lungs with an 
average survival post-diagnosis of 2-3 years. Loss of alveolar type II (ATII) cells and 
impairment of the regenerative capacity of the lung are also characteristic of the 
disease. Mutations in components of the telomere-maintenance enzyme telomerase or 
in proteins important for telomere protection are found both in familiar and sporadic IPF 
cases. Critically short or dysfunctional telomeres can impair tissue regeneration and 
have been established as a risk factor to develop IPF. New therapeutic targets and 
treatments are necessary; however, the lack of mouse models that faithfully 
recapitulate the human disease has hampered new advances.  
Here, we generated two independent mouse models, which develop IPF owing to 
telomere dysfunction. Severe telomere dysfunction in the absence of telomere 
shortening was induced by Trf1 deletion in ATII cells leading to pulmonary fibrosis. 
Mice deficient for telomerase presenting critically short telomeres were treated with low 
dosage of bleomycin to induce IPF. Bleomycin inoculation synergized with short 
telomeres provoking fibrosis in the lungs. We show that both mouse models develop 
pulmonary fibrosis through induction of telomere damage. Loss of lung function owing 
to replacement of lung cell types by fibrotic and inflammatory infiltrates was observed 
in both mouse models. In conclusion, those mouse models provide proof of principle of 
the causal role of DNA damage stemming from dysfunctional telomeres in IPF 
development and identifying telomeres as promising targets for new treatments.  
The mouse model of pulmonary fibrosis owing to short telomeres generated (Tert-
deficient mice subjected to a low bleomycin dose) was used to test the therapeutic 
efficacy of telomerase activation using AAV9 virus carrying the telomerase Tert gene. 
We find that AAV9-Tert preferentially targets ATII cells. AAV9-Tert treatment following 
radiological diagnosis of pulmonary fibrosis resulted in significant reversal of fibrosis 
and full remission in 50% of the mice 7 weeks after diagnosis, while all the mice treated 
with the empty vector still showed severe fibrosis. Reversal of fibrosis in AAV9-Tert 
treated mice was associated with an increase in telomere length in ATII cells, 
decreased DNA damage, and decreased apoptosis and senescence. AAV9-Tert 
treatment increased the percentage of proliferating ATII cells and lead to gene 
expression changes indicative of decreased fibrosis and increased regeneration. These 
results obtained during this Thesis indicate that telomerase gene therapy is effective in 
the treatment of pulmonary fibrosis provoked or associated with short telomeres. 
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γH2AX  Gamma-phosphorylated Histone 2 variant A.X 
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ATII   Alveolar Type II cell 
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I. Idiopathic pulmonary fibrosis 
Idiopathic pulmonary fibrosis (IPF) is a life-threatening lung degenerative disease, 
which lacks current effective treatments and affects only in the US around 100.000 
people (Armanios, 2012; King et al., 2011). The mean survival time upon diagnosis is 
of only 2 to 3 years (King et al., 2011). The clinical course of the disease is 
characterized by a progressive decline in exercise capacity, difficulty to breathe, 
recurrent infections, and severe impairment in lung function, which makes the patients 
dependent on long-term oxygen treatment. IPF is characterized by presence of lung 
scarring, immune infiltrates and inflammation, which in the past two decades has led to 
the exploration of inflammation as a therapeutic target for treatment of the disease 
(Selman et al., 2001). Unfortunately, recent clinical trials for IPF patients based on 
immune suppression had to be interrupted owing to the toxicity of the treatment 
(Idiopathic Pulmonary Fibrosis Clinical Research et al., 2014). More recently, IPF has 
been proposed to be the result of repetitive epithelial cell injury and defective 
regeneration, although the precise molecular cause of the damage and of the defective 
regeneration remains unclear (Cao et al., 2016; Hinz et al., 2007; Ryu et al., 2014). To 
date, lung transplantation is the only therapeutic option for less than 5% of IPF patients 
with very severe disease (Lama, 2009).  
 
Figure 1. Schematic representation of the fibrotic process. Several factors have been proposed to 
induce alveolar epithelium damage such as smoke, pollution, and radiation (adapted from King et al., 
2011). 
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IPF is an age-associated disease, with a mean age at onset between 50-70 years 
(Armanios, 2013; King et al., 2011), affecting men more frequently than women with a 
2:1 ratio (King et al., 2011). Environmental factors such as smoking, radiation or 
pollution, inflict damage to lung epithelial cells inducing recruitment of immune cells 
and fibroblast generating fibrosis (Fig. 1). Those environmental factors are known to 
increase the risk of developing IPF (Armanios, 2013; King et al., 2011). 
II. Idiopathic pulmonary fibrosis: one of the telomere syndromes 
In humans, a number of conditions have been associated with mutations in telomerase 
and other telomere related genes. Therefore, mutations in telomere maintenance 
genes show a variety of pathologies and disease states which have been collectively 
named as “telomere syndromes” (Armanios and Blackburn, 2012), and which affect 
both highly proliferative (bone marrow, gut, skin) and slow proliferative (liver, lung, 
pancreas) tissues. Genes mutated in telomere syndromes are listed as following: 
Gene Syndromes 
TIN2 
   Dyskeratosis congenita 
   Hoyeraal-Hreidersson syndrome 
   Revesz syndrome 
RTEL1 
   Dyskeratosis congenita,  
   Hoyeraal-Hreidersson syndrome 
CTC1    Coats plus 
Apollo    Hoyeraal-Hreidersson syndrome 
TERT, TERC, 
NHP2, NOP10, 
DKC1 
   Idopathic Pulmonary Fibrosis 
   Dyskeratosis congenita 
   Aplastic Anemia 
TCAB1    Dyskeratosis congenita 
 
The most frequent condition of the telomere syndromes is IPF (Armanios, 2013; 
Armanios and Blackburn, 2012). Genome-wide sequencing studies have identified 
SNPs in Tert and Terc loci affecting telomere length associated to IPF development 
(Codd et al., 2013). In particular, mutations in Tert and Terc account for 8-15% of 
familial and 1-3% of sporadic cases (Alder et al., 2008; Armanios, 2013; Armanios et 
al., 2007). Both familial and sporadic IPF cases, indistinctly of telomerase mutations, 
present a telomere length below the 10th percentile of the average normal population 
(Snetselaar et al., 2015). Lately, telomerase mutations have also been found in up to 
Table 1. Telomere syndromes.  
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1% of smokers showing chronic obstructive pulmonary disease (COPD), also leading 
to abnormally short telomeres (Stanley et al., 2015).  
Compelling evidence that telomere shortening contributes to aging and age related 
disease comes from the study of humans and also mice with defective telomerase 
activity (Armanios and Blackburn, 2012; Blasco, 2005, 2007). Thus, one of the 
hallmarks of aging in mice and humans is the progressive shortening of telomeres with 
increasing age (Lopez-Otin et al., 2013). Many studies have already shown that short 
telomeres are sufficient to cause age-related pathologies and decreased longevity in 
telomerase deficient mice, which show premature aging phenotypes in high-
proliferating compartments (bone marrow, gut, skin, testis) (Blasco et al., 1997; Ferron 
et al., 2004; Herrera et al., 1999; Lee et al., 1998; Leri et al., 2003). Importantly, 
telomerase deficient mice show worsening of phenotypes with increasing mouse 
generations owing to inherited progressively shorter telomeres, with the later 
generations showing severe phenotypes and premature death at pre-reproductive ages 
(Garcia-Cao et al., 2002; Herrera et al., 1999; Lee et al., 1998). This phenomenon is 
also observed in humans and indicates genetic anticipation associated with telomerase 
deficiency (Armanios, 2012) (Fig. 2).  
 
Figure 2. Model of genetic anticipation associated to telomerase mutations. (Armanios, 2012) 
Telomeres are represented at the extreme of the chromosome in red. IPF: Idiopathic Pulmonary Fibrosis; 
AA: Aplastic Anemia; DC: Dyskeratosis Congenita. 
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Disease anticipation is found in human families with telomere syndromes as well as in 
mice. Generally, the mutation first manifests in adults with pulmonary fibrosis and the 
more severe phenotypes appear in paediatric populations (immunodeficiency) and 
young adults (aplastic anaemia) from the next generations (Armanios, 2012, 2013) 
(Fig. 2). 
In spite of pulmonary fibrosis and emphysema being the most frequent manifestations 
of telomere defects in humans, telomerase-deficient mice with critically short telomeres 
do not spontaneously develop pulmonary disease. Exposure to cigarette smoke, which 
is known to accelerate pulmonary fibrosis onset in humans, induces emphysema in 
telomerase-deficient mice, but no IPF was observed (Alder et al., 2011). It has recently 
been shown that alveolar progenitor senescence induced by telomere dysfunction is 
sufficient to recapitulate the regenerative defects, inflammatory responses and 
susceptibility to injury that are characteristic of human telomere-mediated lung disease 
although no fibrosis was reported in this mouse model (Alder et al., 2015). These 
findings suggest that additional damages, or a telomere damage of higher severity, 
may be required for IPF onset in mice with short telomeres.  
III. Mouse models for pulmonary fibrosis 
To study the fibrotic process in IPF and the evolution of the disease several animal 
models have been developed. They have been useful to identify an important number 
of key cells, mediators and mechanisms linked to pulmonary fibrosis. However, mouse 
models that faithfully recapitulate the molecular features of the human disease and that 
aid to find new therapeutic strategies have not yet been developed. Following, I will list 
the principal mouse models for pulmonary fibrosis existing to date: 
- DNA damaging agents 
Bleomycin inoculation is the most used and best characterized mouse model for 
pulmonary fibrosis. The drug was isolated from Streptomyces verticillatus and found to 
be effective against tumors (Umezawa, 1974; Umezawa et al., 1967). Bleomycin has 
been used in a wide variety of experimental animals and over a range of doses 
administrated either via intraperitoneal, intravenous, subcutaneous, or intratracheal. 
Intratracheal inoculation with bleomycin is the easiest and fastest way to provoke 
pulmonary fibrosis, reason why it is the most commonly used (Moore and Hogaboam, 
2008). This model, however, posses the limitation that fibrosis regresses after 4-5 
weeks (Mouratis and Aidinis, 2011). Bleomycin produces double strand breaks in the 
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DNA from alveolar cells leading to cell death, what induces the recruitment of the 
immune system and of activated fibroblasts, and ultimately leading to fibrosis. 
Ionizing radiation is also used to produce fibrosis, which starts to appear as early as 20 
weeks post-exposure (McDonald et al., 1993). Radiation, as bleomycin, provokes DNA 
damage directly into the lungs. However, its response is considerably slower than the 
induced by bleomycin. 
Silica aerosol instillation induces fibrosis in the lungs, recapitulating fibrotic nodules 
seen in humans due to the focal inflammation where silica particles are located. 
Development of fibrosis takes around 15 weeks. In addition, special instrumentation for 
aerosol delivery is required, making this technique not very suitable for researchers 
(Davis et al., 1998). 
- Transgenic mouse models  
Transgenic models are based on the constitutive or conditional expression of a 
transgene. However, although they have aided to the study of the pulmonary fibrosis 
pathophysiology, none of them mimics the main characteristic of human pulmonary 
fibrosis which is the late adulthood onset (Moore and Hogaboam, 2008).  
TGF-α mouse model: in this model, TGF-α over-expression specifically in ATII cells 
induces severe pulmonary fibrosis, located at peribronchiolar and perivascular regions. 
Alveolar architecture is disrupted owing to fibrotic lesions in the alveoli, which are 
induced by paracrine signalling (Korfhagen et al., 1994). 
IL-11 mouse model: over-expression of IL-11 in club cells originates peribronchiolar 
inflammation mainly by mononuclear cell infiltrates, leading to airways remodelling with 
subepithelial fibrosis. These results suggested an important role of this interleukin in 
IPF (Tang et al., 1996).  
Other transgenic mouse models: Over-expression of inflammation-related genes such 
as IL-13, IL-10, IL-1β or Fra-2/AP-1 have also been shown to originate fibrosis (Eferl et 
al., 2008; Kolb et al., 2001; Sun et al., 2011; Zhu et al., 1999). 
In summary, mouse models that recapitulate more closely the molecular features of 
human disease, including telomere defects, are needed. These new models will aid in 
our understanding of the pathobiology of IPF and will allow more efficient preclinical 
testing of novel therapeutic strategies.  
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IV. Telomeres and the telomerase complex  
Mammalian telomeres are protective structures at ends of chromosomes (Blackburn, 
2001; de Lange, 2005) that consist of TTAGGG repeats bound by a six-protein 
complex known as shelterin (de Lange, 2005). Shelterin complex is composed of 6 
core proteins: the telomere repeat factor 1 and 2 (Trf1 and Trf2), the TRF1-interacting 
factor 2 (Tin2), the protection of telomeres 1 (Pot1), the Pot1-Tin2 organizing protein 
Tpp1 (also known as Tint1, Ptop or Pip1), and the repressor/activator protein 1 (Rap1) 
(de Lange, 2005) (Fig. 3). A minimum length of telomeric repeats is necessary for 
shelterin binding and telomere protection (Blackburn, 2001; de Lange, 2005). Lately, it 
has been demonstrated that shelterin complex is essential for telomeric chromatin 
condensation, what restricts the accessibility of the DNA damage response machinery 
to the telomere (Bandaria et al., 2016). Shelterin also prevents the telomeres from 
degradation and the fusion with other chromosomes (de Lange, 2005). Generation of 
mouse models with ubiquitous deletion of shelterin components showed an early 
embryonic lethality, with the exception of Rap1-deficient mice, highlight the importance 
of shelterins for cell viability and tissue homeostasis (Celli and de Lange, 2005; Chiang 
et al., 2004; Hockemeyer et al., 2006; Karlseder et al., 2003; Kibe et al., 2010; 
Lazzerini Denchi et al., 2006; Martinez and Blasco, 2011; Martinez et al., 2010; Wu et 
al., 2006). 
The catalytic subunit of telomerase, Tert (telomerase reverse transcriptase), is an 
enzyme capable of compensating the telomere attrition produced by telomere 
degradation and/or by the incomplete replication of telomeric repeats associated to 
each DNA replication cycle, through de novo addition of TTAGGG repeats to the 
chromosome ends. To this end, telomerase uses an associated RNA component as 
replication template (Terc, telomerase RNA component) (Greider and Blackburn, 1985) 
(Fig. 3).  
In mice and humans, telomerase is silenced after birth leading to progressive telomere 
shortening associated to cell division throughout lifespan, with the exception of adult 
stem cells which maintain telomerase expression to slow down telomere attrition in the 
stem cell compartment (Canela et al., 2007; Flores et al., 2008; Harley et al., 1990; 
Vera et al., 2012). When telomeres reach a critically short length, this triggers 
activation of a persistent DNA damage response at telomeres and the subsequent 
induction of cellular senescence or apoptosis. In the case of adult stem cells, critical 
telomere shortening impairs their ability to regenerate tissues both in mice and 
humans, leading to several different age-related pathologies (Flores et al., 2005). 
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Interestingly, telomere shortening has been shown to be influenced both by genetic 
factors (i.e., mutations in genes necessary for telomere maintenance) and 
environmental factors (e.g., cigarette smoke has a negative effect) (Armanios, 2013; 
King et al., 2011). 
 
Figure 3. Telomere and shelterin complex structure. (Martinez and Blasco, 2011) 
In this regard, proper telomere capping requires not only a minimum length of telomere 
repeats, but also the integrity of the 6 proteins shelterin complex, binding the telomeric 
repeats (de Lange, 2005). Out of these six shelterin components TRF1 was the first to 
be identified (Chong et al., 1995). Extensive work using genetically modified mouse 
models has shown that TRF1 deletion leads to an immediate and persistent DNA 
damage response at chromosome ends. Thus, TRF1 abrogation leads to severe 
proliferative defects in all the tissues studied, including stem cell compartments, 
recapitulating some of the pathologies associated to telomere syndromes (Beier et al., 
2012; Martinez et al., 2009; Povedano et al., 2015; Schneider et al., 2013).  
Regarding the topic of this thesis, it is interesting that TRF1-interacting shelterin protein 
TIN2 has also been found mutated in telomeres syndromes, suggesting that telomere 
uncapping could also leads to disease. However, the role of shelterin dysfunction in 
pulmonary fibrosis has not been formally addressed. 
V. Telomerase gene therapy to delay aging and age-related diseases 
Critical telomere shortening has been a determinant of aging and longevity. In 
agreement with this, increased TERT expression in the context of cancer resistant 
transgenic mice was sufficient to delay aging and extend mouse longevity by 40% 
(Tomas-Loba et al., 2008). Recently, these findings have been translated into a 
potential therapeutic strategy by using adeno-associated vectors (AAV) to transiently 
activate telomerase in adult tissues (Bar et al., 2014; Bernardes de Jesus et al., 2012). 
In particular, treatment with Tert gene therapy using non-integrative AAV9 vectors in 
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adult mice was able to delay aging and increase longevity by decreasing age-related 
pathologies such as osteoporosis, glucose intolerance, as well as neuromuscular and 
cognitive decline. Furthermore, cancer incidence was not increased in the Tert treated 
mice (Bernardes de Jesus et al., 2012) (Fig. 4). More recently, AAV9-Tert delivery 
specifically to the heart was sufficient to significantly increase mouse survival and heart 
function upon myocardial infarction, which was concomitant with decreased fibrosis 
and increased cardiac myocyte proliferation (Bar et al., 2014). In the case of aplastic 
anemia, AAV9-Tert gene therapy was able to improve survival increasing blood counts 
associated to telomere elongation in bone marrow and peripheral blood mononuclear 
cells in two different mouse models (Bar et al., 2016). All these findings together 
support the notion that telomere shortening is at the origin of age-related diseases and 
that, by delaying or reverting this process with telomerase expression, it is possible to 
postpone and treat more effectively age-associated diseases, such as heart infarct, 
aplastic anemia, and pulmonary fibrosis.  
 
Figure 4. Rescue of age-related tissue regeneration in mice upon telomerase re-expression. 
(Bernardes de Jesus and Blasco, 2012)  
VI. Current treatments for IPF 
Idiopathic pulmonary fibrosis has few available therapeutic options, despite being a life-
threatening lung degenerative disease (King et al., 2011). For the last decades, several 
treatments have been tested to cure IPF patients with no success, i.e. prednisone, 
azathioprine, N-acetylcysteine, anti-inflammatory, and anti-coagulation drugs. 
Strikingly, some of them turn to be harmful for IPF patients when used in combination. 
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This is the case of prednisone, azathioprine and N-acetylcysteine combined treatment, 
what led to the National Heart, Lung, and Blood Institute (NHLBI) to discontinue after 
observing an increase of deaths from 1% in placebo-treated patients to 11% in triple 
therapy patients (Wells et al., 2012). Moreover, anticoagulant drugs were also found to 
be no beneficial and potentially harmful (Noth et al., 2012). On the other hand, based 
on the inflammatory nature of the disease, current anti-inflammatory drugs resulted to 
have no or little success for IPF patients (Ahluwalia et al., 2014; Raghu, 2006). 
Nintedanib and pirfenidone are two recently FDA-approved drugs that have anti-
inflammatory and anti-fibrotic activity. Nintedanib is a small molecule tyrosine kinase 
inhibitor. It targets vascular endothelial growth factor receptor (VEGFR), fibroblast 
growth factor receptor (FGFR), and platelet derived growth factor receptor (PDGFR), 
blocking signalling pathways involved in the fibrotic process (Ahluwalia et al., 2014). In 
the case of pirfenidone, down-regulates the production of growth factors and collagen, 
and thereby reducing fibers deposition. In bleomycin-induced fibrosis mouse models 
displayed an antifibrotic activity when administered in a prophylactic treatment regimen 
(Ahluwalia et al., 2014; Inomata et al., 2014; Oku et al., 2008; Tanaka et al., 2012). 
These drugs are the only two efficient drugs for IPF (Ahluwalia et al., 2014; Karimi-
Shah and Chowdhury, 2015; King et al., 2014). However, they only slow down IPF 
progression with no curative capacity (Hunninghake, 2014; Karimi-Shah and 
Chowdhury, 2015; King et al., 2014).  
Indeed, to date, lung transplantation is the only curative therapeutic option in less than 
5% of IPF patients with severe disease (Lama, 2009). This method is very complicated 
due to the intervention complexity and the post-surgical complications, and it is only 
available to a small minority of IPF patients (Raghu et al., 2011). Thus, development of 
novel and more effective therapeutic strategies to treat the disease are urgently 
needed. 
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The objective of this Thesis is to generate mouse models that recapitulate human IPF 
to be used for the development of novel therapeutic strategies for IPF treatment. I had 
the following specific aims: 
1.- Generation of a mouse model of pulmonary fibrosis due to telomere dysfunction by 
Trf1 deletion. 
2.- Generation of a mouse model of pulmonary fibrosis due to short telomeres and 
telomerase deficiency. 
3.- To test Tert gene therapy as a potential treatment of idiopathic pulmonary fibrosis 
due to short telomeres. 
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Mice and animal procedures 
Trf1flox/flox mice were generated as described (Martinez et al., 2009). To conditionally 
delete Trf1 from alveolar epithelial type II (AT II) cells, homozygous Trf1flox/flox mice 
were crossed with transgenic mice expressing Cre-ERT2 under the control of surfactant 
protein C (SPC) promotor (Rock et al., 2011) as well as with transgenic mice 
harbouring the fluorescence katushka (KFP) protein encoding gene that contains a 
stop cassette flanked by lox sequences, the KFPCAG-lox-STOP-lox allele (Diéguez-Hurtado 
R et al, 2011). Heterozygous Trf1flox/+ SPC-CreERT2 KFPCAG-lox-STOP-lox mice were crossed 
with Trf1+/flox mice to obtain Trf1+/+ SPC-Cre-ERT2 KFPCAG-lox-STOP-lox and Trf1flox/flox SPC-
CreERT2 KFPCAG-lox-STOP-lox mice.  
Tert knock-out and wild-type mice: 
Wild-type mice and Tert-/- of pure C57/BL6 background were used for bleomycin 
intratracheal inoculation procedure. Tert heterozygous mice generated as previously 
described (Liu et al., 2000) were backcrossed to >98% C57/BL6 background. Tert+/- 
mice were intercrossed to generate first generation (G1) homozygous Tert-/- knock-out 
mice. G2 and G4 Tert-/- mice were generated by successive breeding of G1Tert-/- and 
G3Tert-/- mice, respectively 
All mice were produced and housed at the specific pathogen-free barrier area of the 
CNIO, Madrid. All animal procedures were approved by the CNIO-ISCIII Ethics 
Committee for Research and Animal Welfare (CEIyBA) and conducted in accordance 
to the recommendations of the Federation of European Laboratory Animal Science 
Associations (FELASA). 
Tamoxifen treatment 
Tamoxifen was dissolved in corn oil to a concentration of 20 μg/μL. Eighth to ten week 
old Trf1flox/flox SPC-Cre-ERT2 KFPT/+ and Trf1+/+ SPC-Cre-ERT2 KFPT/+ mice were 
intraperitoneally inoculated with 50 μL (1 mg per injection) of tamoxifen solution 3 times 
per week during 6 weeks. 
Bleomycin titration and inoculation 
Decreasing bleomycin concentrations (2.5 mg/kg body weight, 1 mg/kg body weight, 
0.5 mg/kg body weight and 0.1 mg/kg body weight) were intratracheally inoculated to 8-
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10 weeks old wild-type mice. 2 weeks after the inoculation mice were sacrificed and 
analyzed by immunohistochemistry for pulmonary fibrosis. 
Low dose of bleomycin (0.5 mg/kg body weight) or PBS were inoculated to 8-10 weeks 
old wild-type, G2 Tert-/- and G4 Tert-/- mice. 
Viral particle production 
Viral vectors were generated as described (Matsushita et al.) and purified as previously 
described(Ayuso et al., 2014). Vectors were produced through triple transfection of 
HEK293T. Cells were grown in roller bottles (Corning, NY, USA) in DMEM medium 
supplemented with fetal bovine serum (10% v/v) to 80% confluence and then co-
transfected with the following plasmids: plasmid_1 carrying the expression cassette for 
gene of interest flanked by the AAV2 viral ITRs; plasmid_2 carrying the AAV rep2 and 
cap9 genes; plasmid_3 carrying the adenovirus helper functions (plasmids were kindly 
provided by K.A. High, Children’s Hospital of Philadelphia). The expression cassettes 
were under the control of the cytomegalovirus (CMV) promoter and contained a SV40 
polyA signal for EGFP and the CMV promoter and the 3’-untranslated region of the Tert 
gene as polyA signal for Tert. AAV9 particles were purified following an optimized 
method using two caesium chloride gradients, dialysed against PBS, filtered and stored 
at 80°C until use. Mice were treated with viral genome particle in a concentration per 
mouse of 2.5*1012 vg/mL. 
Histopathology, immunohistochemistry and immunofluorescence analysis  
Histopathological analysis of paraffin-embedded lungs was performed in lung sections 
stained with haematoxylin and eosin and Masson’s trichrome using standard 
procedures. To quantify collagen deposition Sirius red staining was performed on 
deparaffinised slides with Picro-Sirius red solution for 1 h.(Broytman et al., 2015) 
Immunohistochemistry stainings were performed with the following primary antibodies: 
rat monoclonal to p53 (POE316A/E9; CNIO histopathology core unit), rat monoclonal to 
p21 (HUGO-291H/B5; CNIO histopathology core unit), mouse monoclonal to phospho–
Histone H2AX (Ser139) (Millipore), rat monoclonal to F4/80 (ABD serotec), p19ARF (5-
C3-1 Santa Cruz Biotechnology), activated-caspase-3 (RyD systems), Interleukin 6 
(ab6672, Abcam) and rabbit polyclonal turbo-RFP (Evrogen).  
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For immunofluorescence, the antibodies used were a rabbit polyclonal anti-TRF1 
(homemade), phospho-H2AX Ser 139 (05-636, Millipore), goat polyclonal anti SPC (C-
19; Santa Cruz Biotechnology), αSMA (CME 305; Biocare Medical) and mouse 
monoclonal, KFP (RF5R; Abcam), and rabbit monoclonal anti Ki67 (0003110QD; 
Master Diagnostica). Images were obtained using a confocal ultraspectral microscope 
(Leica TCS-SP5). Fluorescence intensities were analyzed with Definiens software.  
Lung in-vivo imaging by computerized tomography (CT) 
The acquisition was made on a high-resolution CT system (CT Locus, GE Healthcare) 
specially designed for small laboratory animals. Mice were anesthetized with a 4% rate 
of isoflurane (IsoVet Braun) during the induction and 2% during the maintenance period 
(scanning time). Micro-CT image acquisition consisted of 400 projections collected in 
one full rotation of the gantry in approximately 14 min in a single bed focused on the 
legs, with a 450 μA/80kV X-ray tube. 2-D and 3-D images were obtained and analysed 
using the software program MicroView (GE Healthcare). All procedures were carried 
out according to the European Normative of Welfare and Good Practice (2010/63/UE) 
Spirometry analysis 
Wild-type and G2 Tert-/- mice were placed into a head-out single chamber 
plethysmograph (Harvard Apparatus) for 3-5 min. Data acquisition was performed by 
Pulmodyn W software (from Hugo Sachs Elektronic Harvard Apparatus).  
Transcriptional analysis in paraffin included lungs  
RNA was extracted from two lung paraffin block sections of 20 mm with RNeasy FFPE 
kit following manufacturer instruction (Qiagen, cat. Nº 73504). cDNA was synthesised 
and collagen I and III expression was analysed by qPCR. The primers used for Col1a1 
were Col1a-F (5’-GCCACTCTGACTGGAAGAGC-3’) and Col1a-R (5’- 
CAGCCTTGGTTAGGGTCGAT-3’). The primers used for Col3a1 were Col3a1-F (5’-
AAATTCTGCCACCCCGAACT-3’) and Col3a-R (5’- AGCCTTGGTTAGGATCAACCC-
3’). 
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Telomere analysis  
Q-FISH determination on paraffin-embedded tissue sections was performed as 
described previously (Gonzalez-Suarez et al., 2000). After deparaffinization, tissues 
were post-fixed in 4% Formaldehyde 5min, washed 3x5min in PBS and incubated at 
37ºC 15 min in pepsin solution (0.1% Porcine Pepsin, Sigma; 0.01M HCl, Merck). After 
another round of washes and fixation as above-mentioned, slides were dehydrated in a 
70% - 90% - 100% ethanol series (5min each). After 10 min of air drying, 30l of 
telomere probe mix (10mM TrisCl pH7, 25mM MgCl2, 9mM Citric Acid, 82 mM 
Na2HPO4, 70% Deionised Formamide –Sigma-, 0.25% Blocking Reagent –Roche- 
and 0.5μg/ml Telomeric PNA probe -Panagene) were added to each slide. A cover slip 
was added and slides incubated for 3min at 85ºC, and for further 2h at RT in a wet 
chamber in the dark. Slides were washed 2x15 min in 10 mM TrisCl pH7, 0.1% BSA in 
70% formamide under vigorous shaking, then 3x5min in TBS 0.08% Tween20 and then 
incubated in a 4`,6-diamidino-2-phenylindole (DAPI) bath (4μg/ml DAPI (Sigma) in 
PBS) before mounting samples in Vectashield (VectorTM). Confocal image were 
acquired as stacks every 1 μm for a total of 3 μm using a Leica SP5-MP confocal 
microscope and maximum projections were done with the LAS-AF software. Telomere 
signal intensity was quantified using Definiens software. 
In the case of immuno-FISH, immunofluorescence against SPC was performed as 
described above before start QFISH. Next to secondary antibody incubation tissues 
were post-fixed in 4% Formaldehyde 5min, washed 3x5min in PBS, and after another 
round of fixation as above-mentioned, slides were dehydrated in a 70% - 90% - 100% 
ethanol series (5min each). After 10 min of air drying, 30l of telomere probe mix 
(10mM TrisCl pH7, 25mM MgCl2, 9mM Citric Acid, 82 mM Na2HPO4, 50% Deionised 
Formamide –Sigma-, 0.25% Blocking Reagent –Roche- and 0.5μg/ml Telomeric PNA 
probe -Panagene) were added to each slide. A cover slip was added and slides 
incubated for 3min at 85ºC, and for further 2h at RT in a wet chamber in the dark. 
Slides were washed 2x15 min in 10 mM TrisCl pH7, 0.1% BSA in 50% formamide 
under vigorous shaking, then 3x5min in TBS 0.08% Tween20 and then incubated in a 
4`,6-diamidino-2-phenylindole (DAPI) bath (4μg/ml DAPI (Sigma) in PBS) before 
mounting samples in Vectashield (VectorTM). Confocal image were acquired as stacks 
every 1 μm for a total of 3 μm using a Leica SP5-MP confocal microscope and 
maximum projections were done with the LAS-AF software. Telomere signal intensity 
was quantified using Definiens software. 
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Gene expression analysis  
RNA was extracted from post-caval lobe frozen lungs with RNeasy kit following 
manufacturer instruction (Qiagen, cat. Nº 73504) and RNA integrity analyzed in an 
Agilent Bioanalyzer. cDNA was synthesized and analyzed on Agilent´s Mouse Genome 
DNA microarray, following the manufacturer’s instructions.  
Validation by qPCR for several hits was performed. The primers used were the 
following. 
Table 2. Primer list. 
Gene   Sequence (5' -> 3') Length Tm 
FLIP 
FWD Primer GCTCCAGAATGGGCGAAGTAA 21 62 
RV Primer ACGGATGTGCGGAGGTAAAAA 21 62 
     
MMP-9 
FWD Primer TGG CTT TTG TGA CAG GCA CTT   
RV Primer CCC GAC ACA CAG TAA GCA TTC   
     
Lrp5 
FWD Primer AAGGGTGCTGTGTACTGGAC 20 62 
RV Primer AGAAGAGAACCTTACGGGACG 21 61 
     
Bid 
FWD Primer GCCGAGCACATCACAGACC 19 63 
RV Primer TGGCAATGTTGTGGATGATTTCT 23 61 
     
Bax 
FWD Primer TGAAGACAGGGGCCTTTTTG 20 60 
RV Primer AATTCGCCGGAGACACTCG 19 62 
     
Lrp6 
FWD Primer TTGTTGCTTTATGCAAACAGACG 23 61 
RV Primer GTTCGTTTAATGGCTTCTTCGC 22 60 
     
APC 
FWD Primer CTTGTGGCCCAGTTAAAATCTGA 23 61 
RV Primer CGCTTTTGAGGGTTGATTCCT 21 61 
     
Fzd5 
FWD Primer GGTGTGCCAGGAAATCACG 19 61 
RV Primer CACAAGCGGCCAGAATTGG 19 62 
     
Ctnnb1 
FWD Primer ATGGAGCCGGACAGAAAAGC 20 63 
RV Primer CTTGCCACTCAGGGAAGGA 19 61 
     
MCL1 P3 
FWD Primer CAAAGATGGCGTAACAAACTGG 22 60 
RV Primer CCGTTTCGTCCTTACAAGAACA 22 61 
     
CenpQ 
FWD Primer AATGTGCAACACTGAAAGTCCC 22 61 
RV Primer ATTCTGGTTTGGAATTAGTGCCA 23 60 
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Microarray analysis 
Microarray background subtraction was carried out using normexp method. To 
normalize the dataset, we performed loess within arrays normalization and quintiles 
between arrays normalization. Differentially expressed genes were obtained by 
applying linear models with R limma package (Smyth GK) (Bioconductor project, 
http://www.bioconductor.org). To account for multiple hypotheses testing, the estimated 
significance level (p value) was adjusted using Benjamini & Hochberg False Discovery 
Rate (FDR) correction. Those genes with FDR <0.05 were selected as differentially 
expressed between controls and tumors.  
Gene set enrichment analysis 
Gene set enrichment analysis (GSEA) was applied using annotations from Biocarta, 
KEGG, NCI pathways and Reactome. Genes were ranked based on limma moderated 
t statistic. After Kolmogorov-Smirnoff testing, those gene sets showing FDR <0.05, a 
well-established cut-off for the identification of biologically relevant gene sets 
(Subramanian et al., 2005), were considered enriched between classes under 
comparison. 
Flow cytometry 
Cells were isolated from mouse lungs of both groups AAV9-Tert and AAV9-empty 
vector. Lungs were extracted and introduced in HBBS buffer with antibiotic and 1% 
BSA. Separate the lobules of the lung on a dish mince them with a scalpel. Transfer 
them to a GentleMacs tube with HBBS, antibiotics,, 1% BSA, DNAse I (60 units/mL) 
(Sigma, DN25) and collagenase type I (70 units/mL) (GIBCO, Cat. Number 17100). 
Then we run the GentleMac program “lung 1”, after the program incubate the sample at 
37ºC for 30 minutes and at the end we run the GentleMac program “lung 2”. Cell 
suspension was filtered through a 40μm strainer and then centrifuge 1200 rpm 5 min. 
Cells were resuspended in 2 mL ACK Lysis Buffer to lyse red blood cells. Incubated for 
4 min. at room temperature. We added DMEM without serum to wash, centrifuged cells 
and discarded the supernatant. Cells were resuspended in PBS with EDTA (1mM), 
Hepes (25 mM) and 3% FBS and stained with LysoTracker as described in commercial 
protocol (Molecular Probes, LysoTracker Green DND-26, Cat. Num. L7526) and the 
following antibodies from Pharmingen (BD Biosciences, San Jose CA): PE anti-mouse 
CD45, PE anti-mouse CD31, APC anti-mouse EpCAM. DAPI (Sigma, St Louis MO) 
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was used to identify dead cells. Data was collected and the defined populations (CD45-
CD31-EpCAM+ LysoTracker+ and LysoTracker-) were sorted using an InFlux cell 
sorted (BD, San Jose CA), we excluded cell aggregates by using pulse processing in 
the scatter signals and dead cells in the basis of DAPI staining. All data was analyzed 
using FlowJo software v9.8.5 (Treestar, Ahsland OR). 
Statistical analysis 
An unpaired t-student test was used to calculate statistical significance of p21, p53, 
p19, C3a and γH2AX markers by immunohistochemistry and interstitial fibrosis by 
Sirius red staining. A Log Rank test was used to calculate the statistical differences in 
the survival curves of the different mice cohorts. 
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Generation of Trf1 conditional knock-out mouse model 
To generate a Trf1 conditional knock-out mouse model we took advantage of previous 
work from our lab (Martinez et al., 2009). The Trf1flox/flox locus contains two loxP sites 
flanking the exon 1 of the gene (Fig. 5). Mice were crossed with a mouse strain 
carrying an inducible CreERT2 recombinase that is expressed under the control of 
surfactant protein C promoter (Sftpc), a specific marker for ATII cells (Fig. 5). This Cre 
recombinase is fused to an estrogen receptor (ERT2) which sequesters Cre into the 
cytoplasm until an agonist is provided (i.e., tamoxifen) and relocates Cre into the 
nucleus, where it can produce direct recombination. We also introduced a fluorescence 
reporter gene to control Cre activity and to identify cells undergoing Trf1 deletion. In 
particular, transgenic mice harboring the katushka fluorescence protein (KFP) whose 
expression is regulated by a transcriptional stop cassette flanked by loxP sequences   
KFPCAG-lox-STOP-lox were used (Dieguez-Hurtado et al., 2011) (Fig. 5). Upon 
intraperitoneal injection of tamoxifen (TMX) we induced Cre relocation and the 
subsequent TRF1 abrogation and KFP expression specifically in ATII cells. 
 
Figure 5. Genetic mouse model. Trf1
lox/lox
, KFP 
Lox-STOP-Lox 
and SPC-Cre
ERT2 
alleles are depicted before 
and after Cre-mediated excision.  
Trf1 deletion in the lung induces pulmonary fibrosis and decreases mouse 
survival 
First, we validated the model by inducing CreERT2 activation by intraperitoneal TMX 
administration three times per week (Fig. 6A). After two weeks of tamoxifen-treatment, 
we quantified the amount of KFP positive cells in the lungs of Trf1lox/lox SPC-CreERT2 
KFPlox-STOP-lox mice and of Trf1+/l+ SPC-CreERT2 KFPlox-STOP-lox control mice by 
immunohistochemistry. In both genotypes, we found that 1 week after TMX treatment 
approximately 14% of the total lung cells were KFP positive (Fig. 6B; see also Fig. 
10A) what is in agreement with the previously reported abundance of ATII cells         
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(12-15%) in whole lung cell population (Dobbs, 1990; Van der Velden et al., 2013). We 
next confirmed Trf1 deletion in the lungs of Trf1lox/lox SPC-CreERT2 KFPlox-STOP-lox mice by 
PCR amplification of the Trf1Δ/Δ alleles (Fig. 6C). In addition, triple immunofluorescence 
staining against SPC, KFP and TRF1 clearly demonstrated that the totality of the SPC 
positive cells were also KFP positive, as well as these cells stained negative for TRF1 
in the lungs of Trf1lox/lox mice (Fig. 6D,E). These results indicate efficient Cre expression 
in ATII cells and Trf1 deletion in the lungs of Trf1lox/lox SPC-CreERT2 KFPlox-STOP-lox mice. 
 
Figure 6. Efficient Trf1 deletion in alveolar type II cells upon tamoxifen administration. (A) 
Intraperitoneal TMX treatment and in vivo imaging schedule. 8-10 week old mice were IP injected with 
TMX three times a week during six consecutive weeks. At week 5 and 9 from the beginning of the TMX 
treatment, mice were analyzed by computerized tomography (CT) and at week 16 the remaining alive mice 
were sacrificed for histological analysis. (B) Representative images of immunohistochemistry for KFP 
staining of Trf1
+/+
 SPC-Cre-
ERT2
 KFP
CAG-lox-STOP-lox
 and Trf1
flox/flox
 SPC-Cre
ERT2
 KFP
CAG-lox-STOP-lox
 lung 
sections after one week of TMX treatment. The percent of KFP positive cells with regards to the total lung 
cell population is indicated. (C) Analysis of Trf1 excision by PCR in lung samples. Notice that lung cell 
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populations that are not alveolar type II give rise to TRF1
lox
 allele amplification. (D) Representative images 
of triple immunofluorescence staining of KFP (purple), SPC (green) and TRF1 (red) in Trf1
+/+
 SPC-Cre-
ERT2
 
KFP
CAG-lox-STOP-lox
 and Trf1
flox/flox
 SPC-Cre
ERT2
 KFP
CAG-lox-STOP-lox
 lung sections after two weeks of TMX 
treatment. (E) Quantification of the percent KFP and TRF1 positive cells with regards to SPC positive cells. 
Interestingly, 4 to 8 weeks after TMX treatment, we observed that 42% of the TRF1-
deficient mice of both genders (this increased up to 65% in male mice) showed an 
abnormal CT pattern compatible with fibrosis, while none of the wild-type animals 
showed this CT pattern (Fig. 7A,B). This abnormal radiological pattern is characterized 
by presence of reticular opacities with honeycombing, also typically found in human 
pulmonary fibrosis patients (Fig. 7A) (Ryu et al., 2014).  Notably, the radiologic lesions 
detected by CT occupied the large majority of the lungs (up to 100% of the lung area), 
indicative of very severe lesions (Fig. 7C). In agreement with this severity, TRF1-
deficient mice showing these lesions had to be sacrificed during the first 8 weeks after 
the TMX treatment owing to severe respiratory defects, i.e. laboured and heavy 
breathing, leading to a significantly decreased survival compared to the wild-type mice 
(Fig. 7D). 
 
Figure 7. Trf1 deletion in ATII cells provokes abnormal CT pattern in lungs and affects mouse 
survival within 8 weeks. (A) Representative CT images of Trf1
+/+ 
and affected Trf1
Δ/Δ
 lungs. (B) Percent 
of mice of both genders or only males with abnormal CT pattern at week 9 post beginning of TMX 
treatment. χ
2 
test was used for statistical analysis. (C) Quantification of the affected lung volume. T-test 
was used for statistical analysis. (D) Survival curve of Trf1
+/+
 (n=15) and Trf1
Δ/Δ
 (n=12) mice. Log-Rank test 
was used for statistical analysis of survival curve. 
To confirm pulmonary fibrosis as the cause of abnormal radiological pattern observed 
in TRF1-depleted lungs, we performed full histopathology of the lungs upon mouse 
sacrifice. As pulmonary fibrosis is characterized by formation of fibrotic scars, we 
determined the presence of collagen fiber deposits by using Masson´s trichrome 
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staining (Methods). We observed that more than 40% of the TRF1-deficient mice of 
both genders and 65% of male mice showed pathological findings characteristic of 
pulmonary fibrosis (Fig. 8A,B). In particular, these mice showed extensive pneumonia 
(between 40-50% of the lung parenchyma affected), inflammatory infiltrates consisting 
mainly of macrophages with hemosiderin content indicative of traumatic haemorrhage 
and intense inflammation that were absent in wild-type lungs (Fig. 8A). In agreement 
with human findings, we also detected increased presence of macrophage infiltrates 
and the activation of an inflammatory response as indicated by specific staining against 
F4/80 and against interleukin 6, respectively (Fig. 8A). Deposition of collagen fibers is 
also visualised by Sirius red staining using polarized light for detection (Methods) 
(Broytman et al., 2015). We detected six-fold higher amount of collagen fibers in the 
Trf1 deleted fibrotic lungs compared to the wild-type controls (Fig. 8C,D). This was also 
confirmed by higher collagen expression levels in TRF1-depleted lungs (Fig. 8E). In 
addition, we also observed increased number of α-smooth muscle actin (αSMA) 
positive myofibroblast, which have been associated to fibrotic foci (Zhang et al., 1996) 
(Fig. 8F,G). Together, these findings confirm extensive fibrosis as the consequence of 
TRF1 depletion in ATII cells.  
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Figure 8 (previous page). Histopathological confirmation of pulmonary fibrosis and inflammatory 
phenotype in affected Trf1
 Δ/Δ
 mice. (A) Representative hematoxylin & eosin, Masson’s trichrome, F4/80 
and interleukin 6 staining images of Trf1
+/+ 
and affected Trf1
Δ/Δ
 lungs. Different types of infiltrates; 
macrophages and hemosiderophages (red arrow heads), polymorphonuclear leukocytes (orange arrow 
heads), lymphocytes (blue arrow heads) and collagen deposits (black arrow heads) are indicated. 
Amplification of Masson’s trichrome images is shown. (B) Percentage of mice of both genders or only 
males diagnosed with pulmonary fibrosis by histopathological analysis. T-test was used for statistical 
analysis (C) Representative images of Trf1
+/+ 
and affected Trf1
Δ/Δ
 lung sections stained with Sirius red and 
visualized by bright field and polarized light where collagen fibers are bright orange. (D) Percent of lung 
area filled with collagen fibers.              (E) Transcriptional levels of collagen expression of collagen in 
Trf1
+/+ 
and affected Trf1
Δ/Δ
 lungs. (F-G) Representative image and quantification of αSMA positive 
myocytes staining.  
Trf1 deletion in alveolar type II cells leads to cell death without inducing telomere 
length changes in lung cells  
We investigated the underlying molecular consequences of Trf1 deletion in the lung 
that trigger the disease. First, we considered the hypothesis that TRF1 deficiency may 
lead to decreased telomere length by forcing extra proliferation of the remaining non-
deleted Trf1 lung epithelial cells. In particular, we recently described that Trf1 deletion 
in the bone marrow led to depletion of the stem cell compartment and to extra 
proliferation of the remaining non-deleted Trf1 progenitor cells, leading to very rapid 
telomere shortening in the bone marrow (Beier et al., 2012). To this end, we performed 
Q-FISH directly on lung sections (Methods). However, we did not observe differences 
either in the mean telomere fluorescence intensity or in the mean nuclear telomere 
fluorescence between tamoxifen treated Trf1lox/lox SPC-CreERT2  KFPlox-STOP-lox mice and 
wild-type controls (Fig. 9A-B,E). Similarly, we did not see increased frequency of 
telomere spots with low fluorescence (<50 and <60 arbitrary units of fluorescence) 
corresponding to the 10th and 20th percentile of the wild-type telomere fluorescence 
distribution in the Trf1-deficient lungs, which are indicative of presence of very short 
telomeres (Fig. 9C-E). These results are in agreement with the fact that lung is a low 
proliferative compartment with a cell turnover estimated to be less than 2% per week in 
alveolar epithelial cells (Alder et al., 2011). 
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Figure 9. Trf1 deletion in alveolar type II cells does not induce telomere length changes in lung 
cells. (A-D) Individual mean telomere length (A), total mean nuclear telomere length (B), percent of short 
telomeres <50 a.u.f corresponding to 10
th
 percentile of wild-type telomere distribution (C) and percent of 
short telomeres < 60 a.u.f. corresponding to 20
th
 percentile of wild-type telomere distribution (D) in Trf1
+/+ 
and Trf1
Δ/Δ
 lungs. (E) Representative images of telomere Q-fish analysis.  
Interestingly, we observed that the initial amount of KFP-positive cells (15% for both 
genotypes) dramatically decreased in Trf1 deleted lungs compared to wild-type lungs 
around 6 to 8 weeks after TMX treatment (Fig. 10A,D), which strongly suggests 
elimination of ATII cells as a consequence of Trf1 deletion. Indeed, at death point, 
while Trf1 wild-type lungs showed a 12% of cells being KFP-positive corresponding to 
the totality of ATII cells (Dobbs, 1990; Van der Velden et al., 2013), Trf1-deleted fibrotic 
lungs presented less than 5% of ATII cells indicating that two third of these cells have 
been eliminated in the course of the experiment (Fig. 10A,D).  
Abrogation of TRF1 in proliferative tissues such as the stratified epithelia induces 
telomeric DNA damage and a rapid DNA damage response characterized by the 
activation of p53/p21 pathways (Martinez et al., 2009). Thus, we set to investigate 
these pathways in the lung. Immunohistochemistry analysis of lung sections readily 
revealed that TRF1-depleted ATII cells presented a significant increase in the amount 
of p53 and p21 positive cells, indicative of cellular senescence (Fig. 10B-D). The 
number of p21 positive cells relative to KFP positive cells was progressively increasing 
throughout the course of the experiment. Further supporting the induction of cellular 
senescence, we also detected increased numbers of the p19 protein in TRF1-depleted 
lungs (Fig. 10C-D) (Collado et al., 2007). In addition, we also detected increased 
numbers of cells positive for active caspase 3 (C3a) in TRF1-depleted lungs, indicative 
of apoptosis (Fig. 10C-D). Thus, both senescence and apoptosis are induced as the 
consequence of TRF1 ablation in ATII cells. 
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Double immunofluorescence staining against γH2AX and TRF1 antibodies showed a 
significant progressive increase in the number of γH2AX-positive damaged cells 
reaching 10% of the total lung cell population at 6-8 weeks after the beginning of TMX 
treatment (Fig. 10E-F). Those cells were negative for TRF1 staining demonstrating that 
TRF1 abrogation results in telomeric DNA damage (Fig. 10E-F). Given that wild-type 
lungs did not show damaged cells (<1% of total lung cells) and that the percent of 
damaged cells out of the total lung cells in Trf1-deleted lungs (10%) correspond 
approximately with the number of the totality of alveolar type ATII cells (10-15%) 
(Dobbs, 1990; Van der Velden et al., 2013), our observations suggests that at least 
90% of the total alveolar type II cells lacking TRF1 show DNA damage. This increase in 
γH2AX positive cells could also be a consequence of the anticipated inflammatory 
response observed in Trf1-deficient lungs (Fig. 8A).  
In summary, these findings demonstrate that acute telomere dysfunction in lung 
epithelial cells, such as that triggered by abrogation of the TRF1 shelterin component in 
ATII cells, is sufficient to rapidly induce massive pulmonary fibrosis in mice through 
induction of DNA damage, p21/p53 cell cycle inhibitors, and elimination of ATII cells. 
Thus, we have generated a mouse model that develops IPF induced by telomere 
dysfunction and in the absence of additional damaging agents. These findings also 
highlight the involvement of ATII cells in the development of pulmonary fibrosis. 
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Figure 10. Trf1 deletion in ATII cells leads to cell death. (A) Quantification of KFP positive cells in 
Trf1
+/+ 
and Trf1
Δ/Δ
 lungs after 1, 2 and 6-8 weeks from the beginning of the tamoxifen (TMX) treatment.    
(B) Quantification of p21 positive cells in Trf1
+/+ 
and Trf1
Δ/Δ
 lungs after 1, 2 and 6-8 weeks from the 
beginning of the TMX. (C) Quantification of p53, p19 and C3a positive cells in Trf1
+/+ 
and Trf1
Δ/Δ
 lungs after 
4-8 weeks from the beginning of the TMX treatment. (D) Representative images of KFP (black arrow 
heads), p21 (purple arrow heads), p53 (orange arrow heads), p19 (green arrow heads) and C3a (red 
arrow heads) immunohistochemistry analysis of Trf1
+/+ 
and Trf1
Δ/Δ
 lungs at 6-8 weeks after the beginning 
of TMX treatment. (E) Quantification of γH2AX positive cells in Trf1
+/+ 
after 1 week TMX treatment and in 
Trf1
Δ/Δ
 lungs after 1, 2 and 6-8 weeks from the beginning of the TMX treatment. (F) Representative images 
of double immunofluorescence against γH2AX and TRF1 in Trf1
+/+ 
and Trf1
Δ/Δ
 lungs after 6-8 weeks from 
the beginning of the TMX treatment. Notice that γH2AX positive cells stain negative for TRF1 in Trf1
Δ/Δ
 
lung sections (white arrow heads). p21, p53 and γH2AX positive cells in B, C and E are normalized to the 
number of KFP positive cells. 
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A low bleomycin dose synergizes with short telomeres to trigger pulmonary 
fibrosis 
As pulmonary fibrosis induced by Trf1 deletion does not lead to short telomeres, which 
are characteristic of familiar and sporadic case of human IPF, we next set to develop a 
mouse model for IPF based on telomerase deficiency and short telomeres. This mouse 
model may recapitulate the short telomere phenotype of human patients. However, 
previous reports showed that mice deficient for the telomerase RNA component Terc 
(Terc-/-), which lack telomerase activity, do not develop IPF. Even when these mice are 
subjected to additional cellular damaging agents like cigarette smoke, emphysema is 
the only pulmonary pathology that develops (Alder et al., 2011). 
Bleomycin is widely used to induce acute pulmonary fibrosis in mice (Mouratis and 
Aidinis, 2011). In particular, intratracheal inoculation in wild-type mice with a single 2.5 
g/kg body weight (BW) dose of bleomycin, leads to development of severe fibrotic 
lesions in the lung as early as two weeks post-inoculation. However, these lesions do 
not progress in time and many of them sporadically regress after 4-5 weeks after 
bleomycin inoculation, most likely owing to lung regeneration by the non-affected cells 
(Mouratis and Aidinis, 2011). This fact has been an important shortcoming for the use 
of bleomycin-induced pulmonary fibrosis mouse models for development of new 
treatments. 
To recapitulate the short telomeres phenotype in IPF development in humans, during 
following experiment of this Thesis, we used a low dose of bleomycin which is not 
sufficient to induce pulmonary fibrosis in wild-type mice but may synergize with short 
telomeres in the context of telomerase-deficient mice (Blasco et al., 1997) (Fig. 11A-
C). To determine the highest bleomycin dose that does not induce pulmonary fibrosis in 
wild-type mice, we subjected wild-type mice to 2.5 mg/kg BW, 1 mg/kg weight, 0.5 
mg/kg BW and 0.1 mg/kg BW of bleomycin. We found that the maximum dose that did 
not induce pulmonary fibrosis in wild-type mice was 0.5 mg/kg BW (Fig. 11C).  Thus, 
we selected this low dose of bleomycin for further experiments. In particular, we 
subjected G2 and G4 Tert-/- mice as well as wild-type mice as controls, to 0.5 mg/kg 
BW of bleomycin and followed by CT (Fig. 11B).  
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Figure 11. Bleomycin dose titration in wild-type mice that does not trigger pulmonary fibrosis. (A) 
Heterozygous Tert
+/-
 mice were intercrossed to generate Tert
+/+
 and G1Tert
-/-
 mice. Successive crosses 
between G1Tert
-/-
 and between G3Tert
-/-
 were set to generate G2 Tert
-/-
 and G4Tert
-/-
 cohorts, respectively. 
8-10 week old Tert
+/+
, G2Tert
-/-
 and G4Tert
-/-
 mice were intratracheally inoculated either with vehicle (PBS) 
(IT-Vh) or with 0.5 mg/kg BW bleomycin (IT-Bl). (B) in vivo follow-up of different mouse cohorts. At week 2, 
6, and 10 mice were analyzed by computerized tomography (CT) and at week 12 mice were sacrificed for 
histological analysis.  (C) Determination of the maximum bleomycin dose that does not induce pulmonary 
fibrosis in wild-type mice. Representative image of wild-type lung sections two weeks after intratracheal 
inoculation of bleomycin at a dose of either 2.5mg/kg BW, 1 mg/kg BW, 0.5 mg/kg BW, 0.1 mg/kg BW or 
0.0 mg/kg BW.  
Two to four weeks after inoculation with a low dose of bleomycin, we observed that 
30% and 25% of G2 and G4 Tert-/- mice, respectively, in contrast to 10% of wild-type 
control mice presented abnormal radiological images of the lung (Fig. 12A-B). When 
only males were taken into account, we observed that 50% and 45% of G2 and G4 
Tert-/- mice, respectively, compared to 20% of wild-type control mice presented 
abnormal radiological images of the lung, indicating a tendency towards more Tert-/- 
males than females presenting abnormal CT patterns (Fig. 12A-B). Interestingly, we 
noted that these abnormal CT pattern disappeared with time in the case of wild-type 
mice, indicating that they could correspond to an inflammatory reaction trigger by 
bleomycin inoculation. In contrast, after 10 weeks both G2 and G4 Tert-/- mice were still 
showing an abnormal CT pattern, and lesions were approximately 50% of the affected 
initial lung volume (Fig. 12C-D).  
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Figure 12. Bleomycin low dose provokes abnormal CT pattern with a higher impact for G2 and G4 
Tert
-/-
. (A) Representative CT images of wild-type, G2
 
and G4 Tert
-/-
 lungs. (B) Percentage of mice of both 
genders or only males with abnormal CT pattern at 10 weeks after bleomycin inoculation. (C) 
Quantification of the abnormal lung volume of affected mice. (D) Longitudinal study of affected lung 
volume behavior in the three groups of study. T-test was used for statistical analysis. 
To confirm the presence of lung disease, we performed full histopathological analysis 
of the lungs from four to ten weeks post-inoculation, using Masson´s trichrome staining 
to visualize fibrotic areas. Strikingly, 50-25% of G2 and G4 Tert-/- mice subjected to low 
dose of bleomycin presented with chronic multifocal pneumonia and extensive 
moderate fibrosis, while none of the vehicle-inoculated G2 and G4 Tert-/- male mice, 
and none of the examined wild-type mice (both bleomycin and vehicle-inoculated) 
showed lung fibrosis (Fig. 13A-B). As observed in the Trf1-deficient model, we 
observed a gender bias towards more males than females showing pulmonary fibrosis. 
In addition, macrophage infiltrates and the induction of an inflammatory response, as 
determined by F4/80 and interleukin 6 stainings, respectively, were readily revealed in 
G2 Tert-/- and G4 Tert-/- lungs inoculated with bleomycin. Both markers were absent in 
wild-type controls (Fig. 13C). These findings were further validated by determination of 
collagen fiber deposition using Sirius red staining visualized by polarized light, which 
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revealed approximately 3-fold increase in collagen deposition in the bleomycin-
inoculated G2 and G4 Tert-/- mice compared to vehicle inoculated controls or to wild-
type mice (both bleomycin and vehicle-inoculated) (Fig. 13D-E). Higher collagen 
expression levels were also confirmed by RT-PCR in the bleomycin-inoculated       
Tert-deficient lungs compared to bleomycin-inoculated wild-type lungs (Fig. 13F). 
Furthermore, we detected increased numbers of αSMA positive myofibroblast in 
telomerase-deficient mice inoculated with bleomycin, which are indicative of lung 
fibrosis (Zhang et al., 1996) (Fig. 13G-H). 
 
Figure 13. Low bleomycin dose synergizes with short telomeres to trigger pulmonary fibrosis.      
(A) Representative hematoxylin & eosin and Masson’s trichrome staining images of Tert
+/+
, G2Tert
-/-
 and 
G4 Tert
-/-
 mice inoculated with either vehicle or 0.5 mg/kg BW bleomycin. To the right, amplification 
Masson’s trichrome images are shown. (B) Percentage of mice of either genders or only males diagnosed 
with pulmonary fibrosis by histopathological analysis. (C-D) Representative images of Tert
+/+
, G2Tert
-/-
 and 
G4Tert
-/-
 lung sections inoculated with 0.5 mg/kg BW bleomycin stained against F4/80 and Interleukin 6 
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(C), and Sirius red visualized by bright field and polarized light where collagen fibers are bright orange (D). 
(E) Percent of lung area filled with collagen fibers. (F) Transcriptional levels of collagen expression in 
Tert
+/+
, G2Tert
-/-
 and G4Tert
-/-
 bleomycin treated lungs. (G-H) Quantification of SMA positive 
myofibroblasts (G) and representative images of wild-type, G2 Tert
-/-
 and G4 Tert
-/-
 lungs treated with 
bleomycin (H).  
The presence of pulmonary fibrosis in the bleomycin-inoculated Tert-/- mice, G2 and G4 
Tert-/- mice are concomitant with the significantly altered respiratory parameters when 
subjected to spirometry compared with their corresponding vehicle-inoculated controls 
or to treated wild-type mice (Methods). In particular, prior to sacrifice G2 Tert-/- mice 
showed significantly decreased tidal volume, inhaled minute volume, and expiration 
influx compared to their corresponding vehicle-inoculated controls or to both bleomycin 
and vehicle-inoculated wild-type mice (Fig. 14A-C). 
To further investigate whether pulmonary fibrosis and lung function impairment in G2 
and G4 Tert-/- mice was accompanied by presence of short telomeres, we performed 
telomere Q-FISH directly on lung sections (Methods). As expected, G2 and G4 Tert-/- 
mice showed significantly lower mean telomere fluorescence as well as a lower mean 
telomere nuclear intensity compared with wild-type controls. In addition, we observed 
higher percentage of telomeres showing low fluorescence (<20 and <25 arbitrary units 
of fluorescence, corresponding to 10th and 20th percentile of the G2 Tert-/- telomere 
distribution) in G2 and G4 Tert-/- cohorts compared with wild-type mice (Fig. 14D-H). 
Interestingly, inoculation with low dose of bleomycin did not affect either mean telomere 
fluorescence or the percent of telomeres with low fluorescence in wild-type mice, 
indicating that this cellular damaging agent does not provoke telomere shortening (Fig. 
14D-H). Bleomycin-inoculated G2 and G4 Tert-/- mice showed a tendency to lower 
telomere fluorescence than the untreated controls, most likely as the consequence of 
additional cell divisions to regenerate the damage lung in the absence of telomerase, 
but this trend did not reach statistical significance (Fig. 14D-H). These results indicate 
that development of pulmonary fibrosis in G2 and G4 Tert-/- mice inoculated with a low 
dose of bleomycin require the presence of short telomeres, as inoculated wild-type 
mice do not develop the disease. These results also suggest that the feature of having 
short telomeres is not sufficient for disease onset, and requires of additional damage in 
mice (i.e., bleomycin inoculation). Our results are in line with human findings showing 
that damaging agents such as smoking increases the risk of developing pulmonary 
fibrosis associated with aging or with telomerase mutations (Armanios, 2013). 
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Figure 14. Decreased pulmonary capacity and telomere shortening in lung tissues of telomerase 
deficient mice. (A-C) Analysis of tidal volume (A), minute volume (B) and expiration flux at 50% (C) in 
Tert
+/+
 and G2Tert
-/-
 mice inoculated with either vehicle or with 0.5 mg/kg BW bleomycin. (D-G) Individual 
mean telomere length (D), total mean nuclear telomere length (E), percent of short telomeres <20 a.u.f 
corresponding to 10
th
 percentile of G2 Tert
-/-
 telomere distribution (E) and percent of short telomeres < 25 
a.u.f. corresponding to the 20
th
 percentile of G2 Tert
-/-
 telomere distribution (G) in Tert
+/+
, G2Tert
-/-
 and G4  
Tert
-/-
 mice intratracheally inoculated either with vehicle (PBS) or with 0.5 mg/kg BW bleomycin. (H) 
Representative images of telomere Q-FISH analysis in Tert
+/+
, G2Tert
-/-
 and G4Tert
-/-
 bleomycin treated 
lungs. Amplified images are shown in the insets. 
Bleomycin enhances the DNA damage response in the lungs of telomerase 
deficient mice 
To determine the amount of DNA damage induced by Tert deficiency per se compared 
to combination of Tert deficiency and bleomycin, we first measured DNA damage foci 
by γH2AX on lung sections, as well as the presence of senescence-associated markers 
p21, p53 and p19 as well as the apoptotic marker active caspase-3 (C3a). Of note, 
bleomycin inoculation induces DNA damage in all three genotypes (Fig. 15A,F). 
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Interestingly, the burden of DNA damage was much higher in the G2 and G4 Tert-/- 
mice inoculated with bleomycin (approximately 5% of total lung cells in both cases) 
compared to the vehicle-inoculated controls (around 1-2% in G2-G4 Tert-/-, 
respectively), and also higher than in the treated wild-type mice (less than 1%) (Fig. 
15A,F). The increase in DNA damage burden in bleomycin-treated G2-G4 Tert-
deficient mice was accompanied by increased percentage of positive cells for p53, p21 
and p19, three well-established markers of cell cycle arrest and cellular senescence 
(Fig. 15B-D,F). Similar to TRF1-depleted lungs, we also found increased number of 
active caspase-3 (C3a) positive cells in bleomycin-inoculated Tert-deficient lungs 
compared to wild-type mice (Fig. 15E-F). 
 
Figure 15. Bleomycin enhances the DNA damage response in telomerase-deficient mouse lungs. 
(A-E) Quantification at time of death of H2AX (A), p53 (B), p21 (C), p19 (D) and C3a (E) positive cells in 
Tert
+/+
, G2 and G4Tert
-/-
 lungs inoculated either with vehicle (PBS) or with 0.5 mg/kg BW bleomycin.       
(F) Representative images at time of death of H2AX, p53, p21, p19 and C3a immunohistochemistry 
staining in G4Tert
-/-
 lungs inoculated either with vehicle (PBS) or with 0.5 mg/kg BW bleomycin. 
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Targeting alveolar type II cells by Tert gene therapy reverses pulmonary fibrosis 
induced by telomere shortening 
We decided to test the potential of the mouse model generated in the first part this 
thesis. To do so, we set to address whether telomerase re-expression in the adult lung 
by using AAV9-Tert vectors could be an effective treatment for pulmonary fibrosis 
associated to critical telomere shortening in mice (Povedano et al., 2015). To this end, 
we used the G2 Tert-deficient mouse model of pulmonary fibrosis induced by critically 
short telomeres and a low bleomycin dose (Povedano et al., 2015).   
We first analyzed which lung cell types were transduced by the AAV9 vectors in adult 
mice. To this end, we intravenously (IV) injected adult wild-type mice with AAV9-eGFP 
and determined the expression of eGFP in the lungs at 2 weeks after inoculation. As 
ATII cells have been previously described by us to be a key target for the induction of 
pulmonary fibrosis owing to dysfunctional telomeres (Povedano et al., 2015), we first 
performed double immunofluorescence against eGFP and surfactant protein C (Sftpc) 
a marker of ATII cells. Strikingly, around 80% of all lung cells positive for eGFP cells 
were indeed ATII cells (Fig. 16A-B), demonstrating that AAV9 has a specific tropism 
for this cell type in the lung. At the virus dosage used (2.5*1012 vg/mL), 17% of the total 
ATII cells were transduced with AAV9 vectors (Fig 16A-B). 
 
Figure 16. Intravenous AAV9-Tert treatment targets ATII cells. (A) Representative image of 
immunofluorescence against GFP (in red) and Sftpc (in green). Mice were injected intravenously in the tail 
with AAV9-eGFP and two weeks later were sacrificed to localize virus cell type target. (B) Quantification of 
percentage of GFP
+
 Sftpc
+
 cells relative to total GFP
+
 cells and to total Sftpc
+
 cells. 
We inoculated telomerase-deficient male mice from the second generation, G2 Tert-/- 
mice, with low doses of bleomycin (0.5 mg/kg BW) to induce pulmonary fibrosis 
(Povedano et al., 2015) to later explore the efficacy of AAV9-Tert therapy in this mouse 
model. Two weeks after bleomycin inoculation, mice were examined by CT to identify 
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those individuals with abnormal lung radiological pattern indicative of pulmonary 
fibrosis (Fig. 17A). In agreement with previous results, approximately 50% of the mice 
showed a radiological pattern consistent with pulmonary fibrosis, including presence of 
reticular opacities with honeycombing, typically found in pulmonary fibrosis patients 
(Povedano et al., 2015). Out of the mice diagnosed with pulmonary fibrosis, half were 
intravenously (IV) injected with AAV9-Tert and the other half with the AAV9-empty 
vector as controls. Upon treatment, all mice were longitudinally followed by thoracic CT 
scan at 1, 2, 4, and 7 weeks after gene therapy treatment (Fig. 17A). One week after 
treatment, all fibrotic lesions in AAV9-Tert treated animals regressed in size while they 
further increased in mice treated with empty vector (Fig. 17B-D). Furthermore, from the 
second week after treatment onwards we observed a significantly faster regression of 
fibrotic lesions at all time-points in the in AAV9-Tert mice compared to those treated 
with the empty vector (Fig. 17B). Indeed, 22% of the Tert treated mice appeared to be 
free of the disease as no abnormal images were detected by CT (Fig. 17C). 
Importantly, 7 weeks after treatment, full regression of fibrotic lesions as detected by 
CT were observed in the AAV9-Tert treated group, while at this time point mice treated 
with the empty vector still exhibited 40% of the original fibrotic volume diagnosed by CT 
(Fig. 17B-D). 
At week 8 after treatment, all mice where sacrificed for full histopathological and 
molecular analysis of the lungs. At this point, we also confirmed Tert overexpression by 
RT-PCR in lungs (Fig. 17E) (Bar et al., 2014; Bernardes de Jesus et al., 2012). As 
control, Tert expression was not detected in the lungs of mice inoculated with empty 
vector (Fig 17E). 
Histopathological diagnosis of fibrosis was performed by Masson´s trichome staining. 
We considered “severe fibrosis” when more than 30% of the lung parenchyma was 
affected by fibrosis; “mild fibrosis” when less than 10% of the lung parenchyma was 
affected; and “cured or non-fibrotic lungs” when no signs of fibrosis were found. 
Histopathologic analysis revealed that at week 8 after treatment, all mice treated with 
the empty vector showed severe fibrosis as indicated by more than 30% of the lung 
parenchyma affected by fibrosis (Fig. 17F-G). In contrast, none of the AAV-Tert treated 
mice showed severe fibrosis at this point. Instead, 50% of Tert-treated mice presented 
mild fibrosis lesions and 50% were completely free of fibrotic lesions (Fig 17F-H). 
Thus, 50% of AAV9-Tert treated mice were cured of lung fibrosis 8 weeks post-
treatment while none of the empty vector treated mice were cured and notice that all of 
them showed severe fibrotic lesions (Fig. 17H).  
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Figure 17. Intravenous AAV9-Tert treatment leads to reversal and remission of pulmonary fibrosis 
(A) 8-10 week old G2Tert
-/-
 mice were intratracheally inoculated with 0.5 mg/kg BW bleomycin and two 
weeks after were diagnosed by CT with pulmonary fibrosis. From those affected mice half of them were 
treated intravenously either with AAV9- empty or AAV9-Tert. (B) CT follow-up was performed at 1, 2, 4, 
and 7 weeks post-treatment and quantify as fold change affected lung volume. (C) Percentage of cured 
mice by CT at week 9 post bleomycin inoculation. (D) CT representative images for every time point of the 
treatment (fibrotic area in red). (E) Transcriptional levels of Tert in lung upon IV tail injection after 8 weeks. 
(F) Masson´s trichrome staining from lung sections to evaluate fibrotic regions at end point (collagen fibers 
in blue; nuclei and erythrocytes in red). (G) Histopathological analysis and fibrosis score from lung 
sections. (H) Percentage of cured mice confirmed by histopathological analysis from AAV9-Tert treated 
mice (n=6) and mice inoculated with empty vector (n=6). 
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In addition, collagen deposition analyzed by Sirius red staining of lung sections at week 
8 after treatment confirmed that AAV9-Tert treated mice presented one-third less 
collagen deposition as compared to empty vector treated animals (Fig 18A-B). In 
agreement with lower collagen deposition and remission of fibrosis, AAV9-Tert treated 
mice also showed significantly reduced number of positive αSMA myofibroblasts, which 
are associated with collagen deposition in human IPF patients (Fig 18C-D), suggesting 
an inactivation of fibrotic foci upon Tert treatment. 
In line with fibrosis regression and healing, we also found a significant decrease in 
F4/80 positive cells indicative of macrophages infiltrates reduction in the remaining 
fibrotic areas from AAV9-Tert treated mice compared with the fibrotic areas from   
AAV9-empty treated mice (Fig 18E-F), what suggests lower inflammation upon Tert 
treatment.  
 
Figure 18. Tert treated mice show lower collagen deposition, less inflammation and decreased 
active fibrotic foci. (A) Representative images of Sirius red staining visualized by polarized light where 
collagen fibers are bright orange from mice treated with AAV9-Tert or empty vector. (B) Percent of lung 
area filled with collagen fibers.  (C) Representative images of F4/80 (macrophage specific marker) 
immunohistochemistry staining in AAV9-empty and AAV9-Tert treated mice. (D) Quantification of F4/80 
positive cells from Tert and empty-treated mice lung sections. (E) Representative images of 
immunofluorescence for αSMA (in red) and DAPI (in blue). (F) Quantification of αSMA positive cells. 
 
Results 
58 
 
Tert overexpression rescues apoptosis and cellular senescence in fibrotic lungs 
Short dysfunctional telomeres have been previously shown to trigger a persistent DNA 
damage response (DDR) characterized by increased γH2AX foci, increased expression 
of p21 and p53 cell cycle arrest and senescence markers, as well as induction of 
apoptosis (Hemann et al., 2000; Meier et al., 2007).  Indeed, we previously described 
that mice with pulmonary fibrosis owing to short telomeres also show increased γH2AX 
foci, increased expression of p21 and p53, as well as induction of apoptosis in the 
lungs (Povedano et al., 2015). Interestingly, we found that mice with pulmonary fibrosis 
treated with AAV9-Tert showed a significantly reduction of DNA damage markers as 
indicated by lower percentage of positive cells for γH2AX in the lung compared to mice 
treated with empty vector (Fig. 19A-B). We also found a significant reduction in the 
abundance of p21 and p53 positive cells in the AAV9-Tert treated mice compared to 
those treated with empty vector (Fig. 19A,C-D), as well as a significant decrease in 
apoptosis as indicated by percentage of cells positive for caspase-3 in the Tert-treated 
mice (Fig 19A,E). These results indicate that Tert re-expression in the adult lungs of 
mice with pulmonary fibrosis leads to decreased DNA damage and apoptosis, as well 
as a reduction in the percentage of cells positive for p53 and p21, suggestive of 
decreased cell death and senescence in the lung. 
In order to specifically determine senescence cells in the lungs, we performed whole 
mount staining for SA-β-galactosidase assay in mice diagnosed with pulmonary fibrosis 
and treated with either AAV9-Tert or empty vectors. While senescence cells were 
readily detected in mice diagnosed with pulmonary fibrosis and treated with the empty-
vector, they were undetectable in the residual fibrotic areas present in few AAV9-Tert 
treated lungs at the end of the experiment (Fig 19F-G). These findings indicate that 
Tert treatment rescues DNA damage, apoptosis and cellular senescence in mice 
diagnosed with pulmonary fibrosis owing to critically short telomeres. 
 
 
Figure 19 (next page). Tert-treated mice show reduced DNA damage and subsequent decreased 
senescence and apoptosis. (A) Representative images for the markers γH2AX, p53, p21, p19 and 
Caspase-3 active (C3a) from both groups. (B-E) Quantification of H2AX (B), p53 (C), p21 (D) and C3a (E) 
positive cells in lungs treated either with Tert or empty vector. (F) Representative pictures from fast red 
staining in whole mount SA-β-Gal tissue sections. (G) Quantification of SA-β-Gal positive cells per visual 
field. 
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AAV9-Tert treatment results in increased proliferation of ATII cells 
To further understand the molecular mechanisms by which Tert gene therapy results in 
significant remission and healing of pulmonary fibrosis owing to short telomeres, we 
next studied telomere length specifically in the ATII cells of mice treated with either 
AAV9-Tert or the empty vector. To this end, we performed an immuno-FISH 
experiment with an antibody (anti-Sfptc) to detect ATII cells followed by telomere        
Q-FISH analysis. First, we found that ATII cells from mice treated with the empty vector 
showed significantly shorter telomeres and an increased percentage of short telomeres 
compared to the surrounding non-ATII cells (see relative average telomere length and 
percentage of short telomeres of ATII cells compared to non-ATII cells in Fig. 16A,B). 
The fact that ATII cells have shorter telomeres than non-ATII cells in telomerase-
deficient mice is in agreement with our previous findings indicating that they are 
important for the regeneration of lung damage induced by dysfunctional telomeres, 
thus undergone more cell divisions (Povedano et al., 2015). Interestingly, ATII cells in 
mice treated with AAV9-Tert showed the same telomere length and percentage of short 
telomeres than the surrounding non-ATII, suggesting that telomerase treatment is 
preserving telomeres in ATII cells in the context of lung fibrosis (Fig. 20A-C). In 
summary, these results indicate that specific targeting of ATII cells with AAV9-Tert 
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results in improved telomere length homeostasis of ATII cells compared to these cells 
from mice treated with empty vectors. 
 
Figure 20. AAV9-Tert results in telomere length maintenance after tissue regeneration. (A-B) Fold 
change in telomere length in ATII cells telomere length (A) and percentage of short telomeres (B) relative 
to non-ATII cells. (C) Representative images of immuno-QFISH with Cy3Telomere probe (in red), Sftpc (in 
green) and DAPI (in blue). 
We addressed the effects of Tert treatment on the ability of ATII cells to proliferate and 
regenerate the damaged lung tissue upon fibrosis diagnose. To this end, double 
immunofluorescence against the ATII cells specific marker, Sftpc, and the proliferation 
marker, Ki67, was performed (Materials and Methods). We found that Tert-treated mice 
showed a 2-fold increase in Ki67 positive cells in whole lung tissue sections compared 
to controls (Fig. 21D-E). When specifically looking at ATII cells, we observed 2-fold 
increase in the total number of Sftpc positive cells and 2.5-fold increase in Ki67 positive 
ATII cells in AAV9-Tert treated lungs compared to empty vector controls (Fig. 21D,F-
G). These results show that increased Tert expression in ATII cells provokes an 
increased proliferation of ATII cells, suggesting a higher potential for lung regeneration 
and the remission of lung fibrosis. 
 
 
Figure 21. AAV9-Tert results in increased proliferation of total lung cells and specifically ATII cells. 
(A) Representative images of double immunofluorescence against Sftpc (in red) and Ki67 (in red). (B-D) 
Quantification of percentage of Ki67 positive cells (B), Sftpc positive cells (C) and Ki67 positive cells 
relative to Sftpc positive cells (D).   
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AAV9-Tert treatment leads to gene expression changes indicative of higher 
regeneration potential 
We studied gene expression changes induced by Tert expression in the context of lung 
fibrosis. To this aim, we first performed DNA microarray analysis from the post-caval 
lung lobe from mice diagnosed with pulmonary fibrosis which were treated either with 
AAV9-Tert or with the empty vector and sacrificed at 8 weeks post-treatment (5 mice 
were included per group). We found that 53 genes were significantly upregulated 
(FDR<0.05) in AAV9-Tert treated mice compared to mice treated with empty-vector 
(Table 3). We performed Gene Set Enrichment Analysis (GSEA) to address those 
pathways affected by Tert gene therapy in fibrotic lungs. The results showed significant 
differences of signatures related with DNA replication and mitosis, apoptosis, DNA 
repair, the Wnt pathway, the leukocyte transendothelial migration pathway, and 
extension of telomeres (Fig. 22A,B).  Using RT-PCR, we validated a random selection 
of the more differentially expressed genes within these pathways: Apc, Ctnnb1, Fzd5, 
Lrp6, Lrp5, Bim, Flir, Bid, Mcl1, Mmp-9 and Cenpq (Fig. 22C). Upregulation of the 
“extension of telomeres pathway” is in line with improved telomere maintenance in ATII 
cells treated with Tert (Fig. 22B). Similarly, upregulation of DNA replication and mitosis 
pathways (Fig. 22A) is in accordance with increased proliferation of ATII cells (Fig. 
21A,D). Of note, downregulation of the Wnt pathway in AAV9-Tert treated adult lungs 
is in contrast with the notion that Tert can activate Wnt/β-catenin pathway during 
development (Park et al., 2009). Instead, our results go in line with recent findings 
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showing that high levels of the Wnt pathway genes, Lrp5 and Lrp6, are linked to bad 
prognosis of IPF patients (Lam et al., 2014). Interestingly, we found Mmp-9 
upregulation in Tert-treated lungs, in agreement with previous work showing that Mmp-
9 overexpression attenuates fibrosis in bleomycin-induced IPF (Cabrera et al., 2007).  
Gene symbol GeneName adj.P.Val 
Apol9a apolipoprotein L 9a 0.0015 
Oas2 2'-5' oligoadenylate synthetase 2 0.0015 
Apol9a apolipoprotein L 9a 0.0015 
Apol9b apolipoprotein L 9b 0.0015 
Gm4955 predicted gene 4955 0.0015 
Irf7 interferon regulatory factor 7 0.0015 
Ifi27l2a interferon, alpha-inducible protein 27 like 2A 0.0017 
EG545385 predicted gene, EG545385 0.0024 
Oas1a 2'-5' oligoadenylate synthetase 1A 0.0030 
Isg15 ISG15 ubiquitin-like modifier 0.0032 
Oas1a 2'-5' oligoadenylate synthetase 1A 0.0032 
Ifi44 interferon-induced protein 44 0.0032 
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 0.0045 
Mx1 myxovirus (influenza virus) resistance 1 0.0053 
Zbp1 Z-DNA binding protein 1 0.0056 
Oas1f 2'-5' oligoadenylate synthetase 1F 0.0057 
Zbp1 Z-DNA binding protein 1 0.0083 
Isg15 ISG15 ubiquitin-like modifier 0.0083 
Mx2 myxovirus (influenza virus) resistance 2 0.0083 
LOC100048309 similar to interferon activated gene 204 0.0083 
Oasl1 2'-5' oligoadenylate synthetase-like 1 0.0093 
Phf11 PHD finger protein 11 0.0099 
Oasl2 2'-5' oligoadenylate synthetase-like 2 0.0102 
Ccl4 chemokine (C-C motif) ligand 4 0.0117 
Plac8 placenta-specific 8 0.0117 
Oas3 2'-5' oligoadenylate synthetase 3 0.0123 
Ifi204 interferon activated gene 204 0.0132 
Nkg7 natural killer cell group 7 sequence 0.0183 
Plac8 placenta-specific 8 0.0191 
Csprs component of Sp100-rs 0.0217 
Klra23 killer cell lectin-like receptor subfamily A, member 23 0.0219 
Slfn2 schlafen 2 0.0303 
Klra23 killer cell lectin-like receptor subfamily A, member 23 0.0312 
Lgals3bp lectin, galactoside-binding, soluble, 3 binding protein 0.0315 
Ifng interferon gamma 0.0354 
Klra16 killer cell lectin-like receptor, subfamily A, member 16 0.0364 
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Gene symbol GeneName adj.P.Val 
Klra7 killer cell lectin-like receptor, subfamily A, member 7 0.0364 
Mefv Mediterranean fever 0.0364 
LOC635676 hypothetical protein LOC635676 0.0364 
Slfn4 schlafen 4 0.0364 
Cmpk2 
cytidine monophosphate (UMP-CMP) kinase 2, 
mitochondrial 
0.0371 
LOC100041903 similar to putative G-protein coupled receptor 0.0375 
Klra22 killer cell lectin-like receptor subfamily A, member 22 0.0396 
C79246 expressed sequence C79246 0.0396 
Ccl5 chemokine (C-C motif) ligand 5 0.0396 
LOC631406 similar to schlafen 8 0.0414 
Fasl Fas ligand (TNF superfamily, member 6) 0.0435 
Pyhin1 pyrin and HIN domain family, member 1 0.0438 
Ms4a6c membrane-spanning 4-domains, subfamily A, member 6C 0.0456 
Ms4a4c membrane-spanning 4-domains, subfamily A, member 4C 0.0482 
D14Ertd668e DNA segment, Chr 14, ERATO Doi 668, expressed 0.0482 
Klra23 killer cell lectin-like receptor subfamily A, member 23 0.0493 
Gm4902 predicted gene 4902 0.0493 
Table 3. Differentially expressed genes compared between AAV9-Tert and empty vector treated 
fibrotic lungs (FDR<0.05). The FDR is calculated by Benjamini and Hochberg FDR correction. 
 
Figure 22 (next page). Upregulation of GSEAs and DEGs of gene expression profile upon Tert 
overexpression in lungs. (A) Summary table indicating various differentially regulated gene sets 
overregulated in Tert treated mice compared with empty vector. Gene set overregulated in the empty 
vector group is specified between brackets. (B) GSEA plots for the indicated pathways in lung tissue. A 
heatmap of indicated core-enriched genes is displayed on the right of each enrichment plot. Microarray 
genes were ranked based on the two-tailed t-statistic tests obtained from the AAV9-Tert versus AAV9-
empty by pair-wise comparisons. The red to blue horizontal bar represents the ranked list. Those genes 
showing higher expression levels for each cohort are located at the edges of the bar (AAV9-empty; AAV9-
Tert). The genes located at the central area of the bar show small differences in gene expression fold 
changes between both groups. (C) Fold change mRNA expression levels of candidate genes related with 
canonical Wnt pathway, apoptosis, mitosis and transendothelial migration in AAV9-Tert relative to empty 
vector. 
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Interestingly, out of the nine pathways downregulated by Tert (Fig. 23A), four are 
related with fibroblast growth factor receptors; i.e., the FGFR2C, FGFR4, FGFR and 
the FGFR1 ligand binding and activation cascades (Fig. 23A-C). As FGF1-FGFRc 
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over-expression has been shown to contribute to pathogenesis in IPF patients 
(MacKenzie et al., 2015), these findings suggest that Tert treatment impairs fibroblast 
activation, thus facilitating fibrosis regression.  In line with this, we found a trend 
towards downregulation of the TGF-β pathway (FDR=0.2507) in the AAV9-Tert treated 
lungs (Fig. 23D). This is in agreement with our previous findings that Tert 
overexpression in mouse embryonic fibroblasts (MEFs) induces downregulation of 
TGF-β (Geserick et al., 2006). TGF-β pathway has been linked to fibroblast activation 
and differentiation to myofibroblast (Pedroza et al., 2015). Indeed, perfinidone has 
been proven to significantly slow down pulmonary fibrosis progression by blocking 
TGF-β (Hunninghake, 2014; Karimi-Shah and Chowdhury, 2015; King et al., 2014).  
 
Figure 23. Downregulation of fibroblast activation-related pathways in Tert-treated lungs. (A) 
Summary table indicating various differentially regulated gene sets downregulated in Tert treated mice 
compared with empty vector. (B-C) GSEA plots for the indicated pathways in lung tissue. (D) GSEA plot 
for TGF-β pathway in lung tissue. A heatmap of indicated core-enriched genes is displayed on the right of 
each enrichment plot. A heatmap of indicated core-enriched genes is displayed on the right of each 
enrichment plot. Microarray genes were ranked based on the two-tailed t-statistic tests obtained from the 
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AAV9-Tert versus AAV9-empty by pair-wise comparisons. The red to blue horizontal bar represents the 
ranked list. Those genes showing higher expression levels for each cohort are located at the edges of the 
bar (AAV9-empty; AAV9-Tert). The genes located at the central area of the bar show small differences in 
gene expression fold changes between both groups. 
We set to analyze to what cell type the observed gene expression changes 
corresponded. To this end, we compared the AAV9-Tert lung signature with the genes 
normally expressed in different cell populations (The Gene Expression Barcode 3.0). 
Most upregulated genes (0<Fc<1) corresponded to genes specifically expressed by 
ATII cells (Fig. 24A), with a minority of the genes being normally expressed in 
leukocytes or embryonic fibroblasts. Similar findings were found for the downregulated 
genes (-1<Fc<0) (Fig. 24B).  
 
Figure 24. Differentially expressed genes from AAV9-Tert treated mice correlate with ATII cell gene 
expression signature. Heat maps representing the upregulated genes (A) and downregulated genes (B) 
in AAV9-Tert compared to empty vector treated mice that corresponded to ATII cells, lung leukocytes and 
mouse embryonic fibroblast (MEFs). The red/blue bars represent an over/down-expression of the gene in 
this sample compared with the other cohort. 
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To further confirm that gene expression changes stemmed from Tert upregulation in 
ATII cells, we performed gene expression profiling in isolated ATII cells at one week 
after treatment of fibrotic lungs with AAV9-Tert and empty vectors. ATII cells were 
identified as EpCAM+ LysoTracker+ cells, and non-ATII cells as EpCAM+ LysoTracker- 
(Fig. 25A). Expression of the ATII-specific marker Sftpc by RT-PCR was used to 
validate the FACS sorting (Fig. 25B).  FACS-sorted ATII cells from AAV9-Tert treated 
mice showed Tert mRNA expression while it was undetectable in FACS-sorted ATII 
cells from empty vector-treated controls (Fig. 25C). We also validated decreased p53 
and p21 mRNA expression by RT-PCR in ATII cells from Tert-treated mice compared 
with empty vector-treated mice (Fig. 25D,E).  
Importantly, GSEA analysis showed downregulation of p53 signaling pathway and the 
base excision repair pathway, in line with lower DNA damage in lungs from Tert-treated 
mice compared to those from empty vector-treated mice (Fig. 25D,G). ATII cells 
showed downregulation of apoptosis and TGF-β signaling pathways, in agreement with 
lower apoptosis and fibrosis in the lungs from Tert-treated mice (Fig. 25H,I). Together, 
these results further validate that ATII cells are transduced by AAV9-Tert, leading to 
increased telomerase expression, and to downregulation of DNA damage and fibrotic 
pathways.   
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Figure 25. Isolated ATII cells overexpress Tert and show p53 and p21 downregulation. (A) 
Representative dot plots. The epithelial cell population was identified as CD31CD45 double negative and 
from those we looked at the expression of LysoTracker and EpCAM to identify the ATII cells as double 
positive cells. Those cells were isolated by cell sorting. (B) Validation of specific ATII cells marker Sfpc by 
RT-qPCR. (C) Transcriptional levels of Tert in ATII cells from fibrotic lungs upon IV tail injection after 1 
week. (D-E) mRNA expression levels of p53 (C) and p21 (D) genes in ATII cells 1 week post-IV tail 
injection of AAV9 treatment. (F-I) GSEA plots for the indicated pathways in ATII cells. A heatmap of 
indicated core-enriched of the top 14 genes is displayed on the right of each enrichment plot. 
Finally, we find of interest the fact that similar findings were found by us on the 
amelioration of heart function after infarct in mice treated with AAV9-Tert(Bar et al., 
2014). In particular, Tert treatment leads to lower fibrotic scarring of the heart and 
increased cardiac myocyte proliferation concomitant with transcriptional changes 
suggestive of a regenerative signature (Bar et al., 2014). Interestingly, the gene 
expression changes in AAV9-Tert treated lungs at 8 weeks post-treatment correlate 
with the regenerative heart signature described by Haubner et al for neonatal mice 
(Haubner et al., 2012) (Fig. 27) as well as those described in previous works from the 
laboratory in the context of improved cardiac regeneration upon infarct by AAV9-Tert 
treatment (Bar et al., 2014).  
Figure 26. Tert overexpression in fibrotic lungs mimic neonatal 
regenerative heart tissue after infarctation.  GSEA plot for 
LAD/Sham List from Haubner et al. study. 
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Trf1 deletion in ATII cells provokes pulmonary fibrosis 
Telomeres represent a small percentage of the whole genome DNA. However, 
telomeres and shelterins have been demonstrated to be very important for 
chromosomal integrity, cell viability and proliferation (Blasco, 2007; Blasco et al., 1997; 
Lee et al., 1998; Martinez et al., 2009). Thus, constitutive deletion of the shelterin 
components results in embryonic lethality, with the only exception of Rap1 deletion 
(Celli and de Lange, 2005; Chiang et al., 2004; Hockemeyer et al., 2006; Karlseder et 
al., 2003; Kibe et al., 2010; Lazzerini Denchi et al., 2006; Martinez and Blasco, 2011; 
Martinez et al., 2010; Wu et al., 2006). The shelterin complex prevents the telomeres 
from degradation and fusion with other chromosomes (de Lange, 2005). In this Thesis 
we decided to conditionally deplete Trf1 in ATII cells based on previous studies 
showing that Trf1 deletion triggers a strong DNA damage response (DDR), what leads 
to activation of p53 and p21, cell cycle arrest, senescence or apoptosis (Beier et al., 
2012; Martinez et al., 2009; Povedano et al., 2015). In this thesis we tested whether 
telomere dysfunction induced by Trf1 deletion in ATII cells provoked IPF in mice 
without any additional insult. 
Our results showed that telomere dysfunction associated to Trf1 deletion in ATII cells 
induces a high burden of telomere-induced DNA damage (up to 10% of all lung cells; 
and >90% of ATII cells), activating the p53/p21 and p19ARF pathways what leads to 
massive cell senescence and apoptosis in this cell type (Fig. 27). This, combined with 
the fact that TRF1 deficiency provokes decreased ability of stem cells to regenerate 
tissues (Flores et al., 2005; Schneider et al., 2013) leads to development of pulmonary 
fibrosis.  
Our findings are consistent with a model where the lost of ATII cells hampers lung 
regeneration capacity (Barkauskas et al., 2013; Serrano-Mollar et al., 2007). ATII cell 
loss and decreased regenerative capacity associated to severe telomere dysfunction 
trigger aberrant lung healing by fibroblasts eventually leading to scar formation and 
pulmonary fibrosis.  However, our results are in contrast to a recent work showing that 
telomere dysfunction due to Trf2 deletion impairs lung stem function leading to an 
inflammatory response and susceptibility to lung injury, although this did not induce the 
development of pulmonary fibrosis (Alder et al., 2015). In this work, the authors 
challenged the TRF2-depleted lungs with bleomycin (>1mg/kg body weight) leading to 
a high mortality in the first 2 weeks after bleomycin inoculation, thus not having 
sufficient time for IPF to develop (Alder et al., 2015). Moreover, the authors did not 
address the effect of Trf2 deletion in adulthood without any additional challenge with 
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bleomycin (Alder et al., 2015). In conclusion, our results clearly demonstrate that 
induction of telomere dysfunction upon Trf1 deletion in type II alveolar cells is sufficient 
to induce pulmonary fibrosis.  
Short telomeres synergize with damaging agents to cause pulmonary fibrosis 
Short telomeres are considered to be causal factor for aging and age-related diseases 
(Armanios, 2013; Armanios and Blackburn, 2012; Blasco, 2007; Lopez-Otin et al., 
2013). Furthermore, short telomeres are found in familial and sporadic IPF cases 
(Alder et al., 2008; Alder et al., 2011; Armanios et al., 2007). However, mice with short 
telomeres do not develop pulmonary fibrosis (Blasco et al., 1997; Lee et al., 1998). The 
different outcome in humans and in mice can be due to the fact that mouse telomeres 
are longer than human telomeres as well as to absence of environmental insults in 
hosting facility (Alder et al., 2011; Blasco, 2007). It has previously been reported that 
short telomeres synergize with genetic, chemical and surgical damage to develop 
fibrosis in a low proliferative organ such as liver (Rudolph et al., 2000). In this Thesis 
we sought to address whether short telomeres contributed to the development of 
pulmonary fibrosis in mice after bleomycin insult.  
Bleomycin was initially used as a chemotherapeutic for cancer treatment for human 
patients, resulting in some cases in lung toxicity as a side effect (Umezawa, 1974; 
Umezawa et al., 1967). Due to its lung toxicity, bleomycin has been widely used to 
induce pulmonary fibrosis in wild-type mice (Cabrera et al., 2007; Inomata et al., 2014; 
Moore and Hogaboam, 2008; Mouratis and Aidinis, 2011; Oku et al., 2008; Serrano-
Mollar et al., 2007). Inoculation with a high bleomycin dose (> 1 mg/kg) induces DNA 
damage above the tolerated threshold by the lungs in wild-type and Tert-deficient mice 
(Degryse et al., 2012). Interestingly, we demonstrated here that a low bleomycin dose, 
which is well tolerated by wild-type mice, causes full-blown pulmonary fibrosis in 
telomerase-deficient mice due to the additional damage stemming from the short 
telomeres, thus mimicking the human situation (Fig. 27). These mice show activation of 
the p53/p21 and p19ARF pathways, leading to cell senescence and apoptosis. In 
addition, mice with short telomeres show an impaired regeneration capacity what 
hampers lung regeneration leading to fibrosis. In line with this, the fibrotic process is 
common to several degenerative diseases such as heart infarct, kidney fibrosis, liver 
cirrhosis, as well as spinal cord injury (Rudolph et al., 2000; Ruschel et al., 2015). 
Although the origin of the damage in each case can be different, all of them have in 
common the lack of regenerative capacity of the tissue upon injury (Flores et al., 2005). 
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Lately, improving the regenerative capacity of the damage tissues by different 
approaches is being implemented in the clinics (Ruschel et al., 2015). 
We found that female mice were more resistant than male mice to develop pulmonary 
fibrosis associated to telomere dysfunction, further recapitulating the human situation. 
The reasons why women are less prone to suffer pulmonary fibrosis are still unknown. 
Some studies suggested that the history of smoking and occupational exposure are 
risk factors for IPF giving a possible explanation for the differences in gender incidence 
(Ekstrom et al., 2014). Another likely explanation for this could be that Tert is 
transcriptionally activated by estrogens due to the presence of estrogens receptor 
recognition sequence in its promoter. In agreement with this, women have longer 
telomeres than men (Calado et al., 2009; Gardner et al., 2014; Kyo et al., 1999). 
Telomere dysfunction as trigger of IPF 
All these findings together support a model for the pathobiology of human disease. 
Thus, persistent DNA damage stemming from dysfunctional telomeres associated to 
mutations in telomere maintenance genes or telomere shortening as the consequence 
of aging can synergize with additional cellular damages to trigger pulmonary fibrosis. 
We have demonstrated that a high burden of telomeric DNA damage induced by 
severe telomere dysfunction, even in the absence of telomere shortening, is sufficient 
to trigger pulmonary fibrosis in the absence of any additional DNA damage in the 
genome (Fig. 27). In addition, we showed that short telomeres synergize with a lung 
insult, i.e. bleomycin, to induce pulmonary fibrosis. The mouse models generated 
during this Thesis constitute valuable tools for the preclinical testing of potential 
therapeutic strategies.  
 
Figure 27 (next page). Model for pulmonary fibrosis associated to telomeric DNA damage. Depletion 
of TRF1 protein (red circle) from telomeres (orange rectangle) in lung ATII cells leads to a persistent and 
severe DNA damage response at telomeres characterized by increased H2AX (purple star) in 10% of 
total lung cells and up to 90% of alveolar type II cells, and activation of the p53/p21 pathway. Application of 
a low dose of bleomycin (0.5 mg/kg BW dose) to wild-type lungs does not lead to a significant increase in 
the number of damaged cells (less than 1% of total lung cells). The same bleomycin dose in telomerase 
deficient mice with short telomeres enhances significantly the DNA damage burden in lung cells reaching 
6% of total lung cells showing DNA damage, and to activation of the p53/p21 pathway. In both models cell 
loss mediated by senescence and apoptosis leads and impairs regeneration what may lead to aberrant 
lung healing and formation of fibrotic scars. 
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Telomerase as a potential therapy for IPF 
No effective treatments for human IPF have been developed yet, although the role of 
different cell types in the disease and molecular pathways have been studied for a long 
time. In spite of recent therapeutic advances for the treatment of pulmonary fibrosis, 
most of the patients still face a fatal outcome, where the only curative treatment is lung 
transplantation. The recently FDA approved drugs nintedanib and pirfenidone can 
significantly ameliorate pulmonary fibrosis in patients although no full-remissions have 
been observed (Hunninghake, 2014; Karimi-Shah and Chowdhury, 2015; King et al., 
2014). Thus, new therapeutic strategies aimed to cure the disease are still needed.  
We have addressed the potential of telomerase gene therapy in the treatment of 
idiopathic pulmonary fibrosis (IPF) in Tert-/- mice inoculated with a low dose of 
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bleomycin. AAV9-Tert therapy was previously shown to improve both mice fitness and 
longevity (Bernardes de Jesus et al., 2012). In addition, previous work from our 
laboratory showed that AAV9-Tert therapy protects from scarring following myocardial 
infarction as well as increasing survival of mice with aplastic anaemia owing to short 
telomeres without increasing cancer incidence (Bar et al., 2014; Bar et al., 2016). 
We observed that increased Tert expression in ATII cells results in improved telomere 
maintenance and proliferation of these cells, which is concomitant with decreased 
fibrosis, inflammation, DNA damage as well as decreased presence of apoptotic and 
senescence cells. These results are in line with the notion that short telomeres can 
impair the ability of stem cells to regenerate tissues (Blasco, 2007; Flores et al., 2008), 
and with recent findings suggesting that IPF is the result of defective regeneration upon 
repetitive epithelial cell injury (Cao et al., 2016; Hinz et al., 2007; Ryu et al., 2014). In 
this work, we demonstrated that Tert gene therapy (AAV9-Tert) of mice diagnosed with 
pulmonary fibrosis leads to significant regression and in some cases to full remission of 
pulmonary fibrosis at 8 weeks post-treatment.  
Bleomycin-induced pulmonary fibrosis model has been extensively used to explore 
new therapeutic strategies for the last decades. In this model, the therapeutic window 
to address the efficacy of new treatments is short due to the regenerative capacity of 
the lung in wild-type mice. Therefore, the pharmacological treatment under study has 
usually been administrated in a prophylactic manner impeding to reproduce patients 
situation (Inomata et al., 2014; Oku et al., 2008; Tanaka et al., 2012). However, our 
mouse model allowed us to mimic the clinical situation; i.e. first disease diagnosis and 
then treating those affected mice with full-blown pulmonary fibrosis.  
Changes in gene expression profile upon telomerase gene therapy 
We found that Tert treatment leads to changes in gene expression, which are in line 
with increased proliferation of epithelial cells and with a decreased fibrotic response.  
Interestingly, similar findings were found by us on the amelioration of heart function 
after infarct in mice treated with AAV9-Tert (Bar et al., 2014). In particular, Tert 
treatment leads to lower fibrotic scarring of the heart and increased cardiac myocyte 
proliferation concomitant with transcriptional changes suggestive of a regenerative 
signature (Bar et al., 2014).  
Of relevance for this Thesis, we show that AAV9-Tert expression in fibrotic lungs leads 
to downregulation of pathways involved in fibroblast activation and, in particular, of the 
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tumor growth factor β (TGF-β) pathway as early as 1 week after Tert treatment of 
fibrotic lungs. In addition, downregulation of several FGFR pathways were observed at 
8 weeks post-treatment, what indicates that upon Tert gene therapy an antifibrotic 
process is activated. These pathways are known to be important players in IPF both in 
mice and in humans. Indeed, pirfenidone and nintedanib, both recently approved 
treatments for IPF target different fibrotic pathways such us TGF-β or FGFR pathways 
(Inomata et al., 2014; Oku et al., 2008).  
Telomerase as bona fide efficient treatment for IPF 
The available IPF treatments, pirfenidone and nintedanib, do not induce disease 
remission either in patients or in preclinical mouse models (Inomata et al., 2014; Oku et 
al., 2008; Tanaka et al., 2012). The mechanisms of action of either pirfenidone, which 
is an inhibitor of the TGF-β pathway (Inomata et al., 2014; Oku et al., 2008; Tanaka et 
al., 2012), or nintedanib, which is an antagonist of the fibroblast growth factor receptor 
(FGFR), the platelet-derived growth factor receptor (PDGFR), and vascular endothelial 
growth factor receptor (VEGFR), target fibroblast differentiation, survival, and 
proliferation pathways as well as blood vessel activation pathways affecting fiber 
deposition in lung (Wollin et al., 2015).  
We show in this Thesis that AAV9-Tert therapy effectively reverts fibrosis in mice 
diagnosed with pulmonary fibrosis. This is likely due to the fact that AAV9-Tert therapy 
targets one of the molecular causes of the disease, namely short telomeres (Alder et 
al., 2008; Armanios et al., 2007; Povedano et al., 2015). AAV9-Tert treatment results in 
decreased DNA damage and improved proliferative potential of the ATII cells, and 
subsequently in decreased fibrosis and inflammation (Fig. 28).  In contrast, pirfenidone 
and nintedanib act on downstream events, particularly on reducing fibrosis, while the 
molecular cause of the disease (i.e. damaged telomeres and loss of the regenerative 
potential of epithelial cells), persists (Alder et al., 2008; Armanios et al., 2007; 
Povedano et al., 2015).  
In summary, the findings described in this Thesis demonstrate the therapeutic potential 
of Tert gene therapy to efficiently revert and cure pulmonary fibrosis. 
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Figure 28. Tert gene therapy targets the basis of pulmonary fibrosis. Representation of the working 
model in this work presented, highlighting the way of action and main molecular changes provoked by Tert 
gene therapy. 
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Modeling Human Idiopathic Pulmonary Fibrosis 
1. Telomere dysfunction due to Trf1 deletion in alveolar type II cells leads to lethal 
pulmonary fibrosis. 
2. Low dose of bleomycin synergizes with short telomeres to develop pulmonary 
fibrosis. 
 
Telomerase Gene Therapy 
1. AAV9-Tert gene therapy targets alveolar type II cells maintaining their telomere 
length, reduces DNA damage, senescence and apoptosis, and stimulates their 
proliferation, leading to tissue regeneration. 
2. Tert gene therapy constitutes a novel efficient therapeutic strategy for the 
treatment of IPF associated to short telomeres.  
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